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ABSTRACT 
Deuteration is the replacement of a hydrogen atom by deuterium atom in a molecule. The 
replacement begins at the most acidic hydrogen in the molecule. In ATP, the deshielded 
hydrogen is C8-H which is the first replaced during deuteration. During ATP deuteration 
some of the ATP is hydrolysed to ADP concurrently. Using kinetic analysis, it was confirmed 
that the ATP hydrolysis that occurs is 1
st
 order in ATP concentration, while the hydrogen 
replacement is 2
nd
 order. The ATP and its C8 deuterated analogue were tested against three 
enzymes shikimate kinase (SK), acetate kinase (AK) and glutamine synthetase (GS) to 
determine if a kinetic isotope effect (KIE) exists in these systems. With AK and GS, the KIED 
increased as the KIEH decreased, while with SK the KIED decreased as the KIEH increased as 
the concentration of the ATP or deuterated analogue increased. Deuteration of imidazole and 
purine compounds reduced the specific activity of AK or SK at low concentrations in an 
enzyme-catalysed reaction. From a library of imidazole-containing compounds that inhibited 
SK, three compounds were selected and their IC50 values were determined on the SK-
catalysed reaction. These compounds show a differential potency and efficiency between 
their protonated and deuterated analogues when compared in a 1:1 mixture. Synthesized 
purines incorporating three different substituents at N-9 were tested against AK or SK for 
their ability to lower the specific activity of the enzymes used. 
 
KEY TERMS 
Acetate kinase, Glutamine synthetase, Shikimate kinase, Adenosine triphosphate rate order, 
Proton nuclear magnetic resonance, Enzyme activity and Kinetics, Imidazole and Purine 
deuteration.
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ABBREVIATIONS AND ACRONYMS 
Acetyl-CoA Acetyl-coenzyme A 
ADP Adenosine diphosphate 
AK Acetate kinase 
AMU Atomic mass units 
ATP Adenosine triphosphate 
AMP Adenosine monophosphate 
Arg Arginine 
β Beta 
B0 Main magnetic field 
Buffer A 10mM imidazole, pH 7; 10mM MnCl2; 150mM NaCl 
Buffer B 10mM Imidazole, pH7; 10mM MnCl2; 450mM NaCl 
C Column 
C8-H Hydrogen attached to the carbon atom at the eight position (IUPAC numbering) 
C8-D ATP Adenosine triphosphate deuterated on the carbon atom at the eight position (IUPAC 
 numbering) 
C-D  Deuterium covalently bound to carbon 
C-H Hydrogen covalently bound to carbon 
D UV detector 
Da Dalton 
D2O Deuterium oxide 
ATP-d Deuterated adenosine triphosphate  
E Enzyme 
E. coli Escherichia coli 
EC50 Half maximal effective concentration 
EDTA Ethylenediaminetetraacetic acid 
ES Enzyme substrate complex 
GS Glutamine synthetase 
GTP guanosine triphosphate 
H1 Hydrogen atom at position 1 (IUPAC numbering) 
H2 Hydrogen atom at position 2 (IUPAC numbering) 
H6 Hydrogen atom at position 6 (IUPAC numbering) 
HCl Hydrochloric acid 
HPLC High performance liquid chromatography 
HPP Pressure pump 
IC50 Half maximal inhibitory concentration 
IPTG  Isopropyl β-D-1-thiogalactopyranoside 
Irel Relative signal intensities 
IUPAC International Union of Pure and Applied Chemistry 
IUB International Union of Biochemistry 
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KCl Potassium chloride 
KIE Kinetic isotope effect 
LM + Amp100  Liquid medium containing sugars, alcohol organic acids 100mg/ml ampicillin 
Lys lysine 
MgCl2 Magnesium chloride 
MtSK Mycobacterium tuberculosis shikimate kinase 
NaHCO3 Sodium bicarbonate 
NB nucleotide binding 
NMP Nucleoside monophosphate 
NMR Nuclear magnetic resonance spectroscopy 
OD600 Optical Density at 600 nm 
P Product 
PDA Photodiode array 
ppm Parts per million 
PTA Phosphotransacetylase 
RS Solvent reservoir 
S Substrate 
SB Shikimate binding 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SI Injection loop 
SK Shikimate kinase 
SN1 Nucleophilic substitution reaction 1 
TCA Trichloroacetic acid 
TEA Triethylamine 
Thr Threonine 
TLC Thin layer chromatography 
UV Ultraviolet light 
VD Reaction rate of the deutered analogue 
VH Reaction rate of the protonated analogue 
α Alpha 
γ Gamma 
1
H NMR Proton nuclear magnetic resonance spectroscopy 
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INTRODUCTION 
Protein kinases play a central role in cell function as well as in mediating the effects of 
growth factors. These molecules promote cell proliferation and play a critical role in the field 
of medicine, as many diseases arise as a result of protein kinases losing their functional 
integrity (Scapin, 2002). Protein kinases function by modifying other proteins or molecules 
by transferring a phosphate group from higher energy donor molecules like ATP to a specific 
substrate (Buss et al., 2001; Kenyon et al., 2011). This process is called phosphorylation. 
Understanding the mechanism of phosphorylation and its regulation is essential in the design 
of novel chemotherapeutic agents that target kinase enzymes. The International Union of 
Pure and Applied Chemistry (IUPAC) and the International Union of Biochemistry (IUB) 
commission on the classification and nomenclature of enzymes placed the enzymes that 
transfer high energy phosphate bonds from nucleotides into two divisions: the transferases 
(kinases) and ligases (synthetases) (Buss et al., 2001). 
The Enzyme Commission (EC) classification places ligases and transferases in different 
divisions, with the ligases in division 6 and the transferases in division 2. The ligases are 
enzymes catalysing the joining of two molecules with the concomitant hydrolysis of the ATP 
bond, while a kinase is defined as an enzyme which catalyses the transfer of the phosphate 
group from ATP (or GTP) to a substrate containing an alcohol, amino, carboxylate, or 
phosphate group as the phosphoryl acceptor (KENYON, Colin, 2007). The ligases and 
kinases both convert the ATP into either ADP or AMP during phosphorylation. The kinases 
play a critical role in numerous metabolic and signalling pathways, and their substrates may 
be a small molecule, lipid, or protein (Kenyon et al., 2011). 
It has been demonstrated that the C8-H of ATP plays a critical role in the regulation of the 
phosphorylation reaction carried out by ATP (Kenyon et al., 2011). In this study, enzyme 
kinetics techniques were used to compare the specific enzyme activity of a number of kinase 
and synthetase enzymes using either ATP or its C8 deuterated analogue as co-substrate. 
Deuteration involves the substitution of hydrogen (effectively a proton) with deuterium 
(having both a proton and a neutron) in a molecule (Roger Tung, 2010). Also investigated in 
this study was the effect of deuteration on the inhibition of kinase enzymes by imidazole- and 
purine-based compounds and related analogues. Suitable techniques were established for the 
deuteration of these imidazole and purine compounds. The degree of deuteration of the 
analogues was determined using 
1
H NMR. The enzyme assays were carried out by 
determining the concentration of ATP and ADP in assay mixtures by HPLC as an indirect 
measure of enzyme rate. 
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This study was also undertaken to establish a possible mechanistic role of the proton 
equivalent to that of the C8-H of ATP in imidazole- and purine-based compounds in the 
binding of these compounds to the active sites of kinase and synthetase enzymes. In addition, 
the bigger plan was to eventually have these compounds form part of a chemical library of 
deuterated compounds to subsequently be used for the design of novel selective inhibitors for 
kinase and synthetase enzymes. As such, this deuterated chemical library can be considered 
an innovative approach to drug design, having a significant intellectual property potential, 
particularly when applied as a source of molecular probes to ascertain the extent of inhibition 
of a number of kinase and synthetase enzymes mechanistically. 
For the purposes of this investigation, the following hypotheses were followed: 
 The deuteration of ATP at the C8 position alters the enzyme activity profile of kinase 
and synthetase enzymes, which effect is manifest in the reaction. 
 Imidazole and purine compounds deuterated at the position equivalent to C8-H of 
ATP have altered inhibition profiles against kinase enzymes when compared with 
their protonated counterparts. 
The list of objectives which will now apply, are as follows: 
 
OBJECTIVES 
1. To optimise protocols for the deuteration of imidazole- and purine-based compounds 
2. To determine the effect of deuteration of imidazole- and purine-based compounds on 
subsequent enzyme activity using shikimate kinase, acetate kinase and glutamine 
synthetase as model systems 
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CHAPTER 1: DEUTERATION OF ATP, PURINE- AND IMIDAZOLE-
CONTAINING COMPOUNDS 
1.1   Introduction  
1.1.1 General introduction to methodology  
ATP, purine- and imidazole-based compounds have a number of similarities in their chemical 
structures such as aromatic character and at least two nitrogen atoms in their ring systems. 
This chapter will show how these molecules are deuterated and how their deuterated 
analogues may be used as molecular probes. During ATP deuteration, ADP is also formed; it 
is therefore also the aim of this chapter to determine if there is a correlation between the ATP 
proton/deuterium substitution process and hydrolysis of ATP. Nuclear Magnetic Resonance 
(NMR) and High Performance Liquid Chromatography (HPLC) were used to explore the 
qualitative and quantitative analysis of the molecules and their analogues which were 
produced. One dimensional proton NMR (
1
H NMR) protocols were used to measure the 
levels of deuteration in the entire molecule, while HPLC analysis of these samples was used 
to demonstrate the amount of ATP hydrolysed and possible correlation with inhibition of 
these enzyme reactions. Various protocols for the synthesis of purine compounds were 
employed, in order to demonstrate how the different substituents could be incorporated into 
the purine base molecule. Various molecules were synthesised from 2,6-dichloropurine, 
which served as a molecular template for subsequent modification reactions. While thin layer 
chromatography (TLC) shows purity of the sample and/or whether the starting materials were 
transformed to a new product, it does not confirm modification thereof. 
1.1.2 ATP structure and function 
As shown in Figure 1.1, the ATP molecule consists of both a polar as well as non-polar 
region. The polar region consists of a ribose sugar and three phosphates, while the adenine 
moiety makes up the non-polar region (A and B). Being central to its role as the energy 
source for living organisms (Novak, 2011), ATP is also involved in a large number of 
biosynthetic reactions, including transportation of many ions across concentration gradients 
associated with cellular membranes, as well as in the cellular control and signalling functions 
necessary to maintain life of biological entities by various molecular phosphorylation 
mechanisms (Salisu, Kenyon, & Kaye, 2011). 
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Figure 1.1: ATP structure showing the hydrophobic and hydrophilic domains (A). Also 
indicated is the atom numbering of the adenylyl moiety(B) (Salisu et al., 2011; Kenyon  
 et al., 2011). 
1.1.3  Phosphorylation reactions involving the ATP molecule 
In 1894, Emil Fischer introduced the theory that ATP can bind like a substrate to the enzyme 
based on a shape-fitting mechanism that is complementary to a particular enzyme’s binding 
site. Once this bond is formed, a change in the shape of the enzyme then takes place. As 
reported by Burnstock et al. (2010), Fiske and Subbarow were the first to define the 
chemistry of ATP in 1929. In 1941, Lipmann elaborated on the function and structure of ATP 
in the cell (Suwal et al., 2012). In general, many reactions in the cell require phosphorylation 
by ATP as the primary step to make a given compound more reactive. Various moieties, such 
as adenylyl group, which comprises a purine ring fused to a 5-membered imidazole moiety, 
are intimately involved in these chemical reactions and were therefore exploited during the 
course of this investigation.  
Kinases and synthase enzymes use the ATP molecule to phosphorylate alcohol or carboxyl 
groups, or amino acid hydroxyl groups, in the phosphorylation reaction (Kenyon et al., 2011). 
ATP molecules are made up of a nucleoside (adenosine) and three phosphate moieties that 
are linked by phosphoric acid anhydride bonds. The phosphates are labelled as α, β and γ 
based on both their position as well as potential energy that is stored in the respective 
anhydride linkages (Suwal et al., 2012). The farthest phosphate from the ribose ring is 
γ-phosphate group, having the highest chemical potential energy, followed sequentially by 
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the - and then the -phosphate. Figure 1.2 depicts mechanistically how the hydrolysis of 
ATP typically takes place to activate an alcoholic ROH group. 
 
Figure 1.2: Schematic diagram showing ATP-mediated phosphorylation by the attack of  
hydroxyl nucleophile on the γ-phosphate. A phosphorylated molecule is formed, and 
ATP is converted to ADP. 
 
The oxygen atom of a hydroxyl group (from an alcohol or carboxylate) or the nitrogen atom 
from an amine can attack the γ-phosphate of ATP molecule via a nucleophilic acyl 
substitution mechanism. This involves the anhydride bond between the γ- and β-phosphate 
group being broken and the γ-phosphate binding to the nucleophile, to ultimately form the 
phosphorylated molecule (Suwal et al., 2012). Adenosine diphosphate (ADP), is formed as a 
result, and is stabilised by environmental water. 
1.1.4 Deuterium as Molecular Probe 
Molecular deuteration is the substitution of hydrogen (protium or proton), by a deuterium 
(heavy hydrogen) atom, in a compound (Kenyon et al., 2011; Tung, 2010). The deuterium 
atom is a heavier isotope of hydrogen, differing by a single additional neutron. The resultant 
change in atomic mass from 1AMU to 2AMU thereby doubles the atomic mass of hydrogen 
(effectively a naked proton). By the old terminology, the nucleus of deuterium was called a 
deuteron, in contrast to the nucleus of hydrogen, called a proton or protium (Buteau, 2009; 
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Limbach, 1991; Tung, 2010). According to Limbach (1991) and Wade (1999), deuterium was 
first discovered by Urey, Brickwedde and Murphy in 1931 in their study of water electrolysis. 
Despite the many studies which have since been conducted using deuterated molecules as 
probes, few have been done on kinase enzymes, specifically with ATP deuterated at the C8 
position. The mechanism by which ATP is deuterated involves a change between a carbon to 
hydrogen (C-H) and carbon to deuterium (C-D) bonds (Wade, 1999). While the compound 
being deuterated shows slight changes in physical properties, changes in molecular properties 
such as hydrophobicity, chemical molecular mass and pKa are more significant (Tung, 2010). 
Specifically, the C-D bond that is formed is much stronger than the equivalent C-H bond, 
thereby causing a reduced reaction rate if the C-D (H) bond subsequently plays a role in a 
chemical reaction mechanism. The ratio of the reaction rate, in the presence of a deuterated 
molecule, when compared with the reaction rate in the presence of the protonated analogue, is 
called Kinetic Isotope Effect (KIE = VD/VH) (Limbach, 1991). KIED is defined as the ratio of 
the reaction rate in the presence of the deuterated material divided by the reaction rate in the 
presence of the protonated material. The inverse ratio is termed KIEH (Földesi et al., 1996). 
1.1.5 Deuteration of ATP 
ATP contains an adenine group, which is a bicyclic 5,6-fused heterocyclic aromatic 
compound containing four nitrogen atoms in the ring structure. The ATP base fulfils the 
aromatic properties in the adenine molecule by having all carbon atoms in the ring system 
being sp
2
 hybridized to form a resonance stabilised aromatic π-bond system. For the adenine 
molecule to fulfil the Hückel rule, three of the four bonding orbitals of the nitrogen atom are 
also sp
2
 hybridized. One of the characteristics of lone pairs of nitrogen electrons is to cause 
molecules containing these atoms to react differently compared to other aromatic compounds. 
Where ATP molecules are concerned, protons at position 8 and 2 of the adenine ring are the 
most acidic, being the first to be substituted during the deuteration process. 
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1.1.6 Nuclear magnetic resonance spectroscopy (NMR) 
Nuclear magnetic resonance (NMR) spectroscopy is a physical technique that exploits the 
magnetic properties of certain nuclei, such as 
1
H, 
13
C and 
15
N. This property is derived from 
the number of nucleons in an isotope’s nucleus, giving rise to spin quantum numbers and a 
nuclear magnetic moment. A typical NMR instrument has two magnetic poles placed 
opposite each other so as to create the main magnetic field B0, at the centre of which a glass 
tube, containing a sample of interest, is placed (Figure 1.3). The shims or sweep coils adjust 
the main magnetic field B0 around and through the sample, enabling this region to be as 
magnetically homogeneous as possible for each sample. Radio waves are then introduced into 
the sample to allow selective excitation of the spin magnetic moment of each population of 
nuclei in the sample at a specific resonant frequency. Between the sample and the sweep coils 
(shims) is an arrangement of transmitter and receiver coils surrounding the sample, termed a 
sample probe. The probe allows both a radio frequency transmitter as well as a radio 
frequency receiver/amplifier to operate simultaneously on the sample. Specific radio 
frequency pulses are introduced into the sample by the transmitter, stimulating the excitation 
of each distinct type of nucleus in a quantised fashion by absorption of the radio frequency 
waves. The absorption event is detected as a signal output from the sample by the 
receiver/amplifier. These electronic signals generated from the interaction of the magnetic 
field with the magnetic moment of the nuclei in the sample, and subsequently stimulated to 
resonate at a particular radio frequency, are converted by the software to produce a NMR 
spectrum at the Control Console and Recorder. 
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Figure 1.3: A schematic diagram of an NMR spectrometer containing a sample under  
analysis. 
 
Applications of this kind of magnetic resonance technology can provide detailed information 
about the chemical structure, dynamics, reaction state, and chemical environment of interest 
within which sample atoms occur. In essence, when a sample is placed in such a magnetic 
field, the active nuclei of atoms (such as 
1
H or 
13
C) absorb electromagnetic radiation at a 
frequency characteristic of that particular isotope for each atomic nucleus. The resonant 
frequency, energy of the absorption, and the intensity of the signal are proportional to the 
strength of the magnetic field, which can be varied to suit a given sample analysis protocol. 
One dimensional proton NMR (
1
H NMR) is a protocol that is used to determine the proton 
location in the molecular structure of a given sample.  
An advantage of 
1
H NMR spectroscopy, is that it can be used for both qualitative and 
quantitative analysis of molecular structure (Limbach, 1990). Since each nucleus has a 
different resonance ‘range’, when hydrogen is substituted with deuterium, the substitution is 
seen as a loss of signal in a standard 
1
H-NMR of the deuterated molecule (Limbach, 1991; 
Heller, 1968). 
1
H NMR is therefore a convenient technique for quantitatively measuring the 
deuteration process. This process is monitored by observing intensity changes in a specific 
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proton signal in the spectrum that corresponds to a hydrogen atom of interest, as it is replaced 
by deuterium. As seen in Figure 1.5A and B (p.27), deuteration of ATP can be monitored by 
the disappearance of the signals indicated. As the signal due to the proton(s) of interest 
progressively disappears from the spectrum as a function of incubation time, the extent to 
which deuteration has occurred, at specific positions in the molecule of interest, can be 
determined by comparing the integrated value of the signal of interest (Lin & Bersohn, 1968). 
1.1.7 Determination of ATP deuteration reaction rate order 
During ATP deuteration, two processes are observed: (1) some ATP protons are replaced by 
deuterium to form ATP-d, and (2) some of the ATP is hydrolysed to form ADP. In order to 
determine if a correlation exists between hydrogen-deuterium exchange and hydrolysis of 
ATP, it is important to know what the rates of ATP hydrolysis and proton-deuterium 
exchange are, under the same conditions. Since the rate law governing this process can occur 
as 1
st
 or 2
nd
 order reaction rate kinetics, data from both reactions can be tabulated, for 
comparison between the two reactions. To quantify this, high pressure liquid 
chromatographic (HPLC) was used to determine the amount of ATP hydrolysis during 
deuteration, while 
1
H NMR protocols were used to determine the rate of deuteration of ATP. 
Once both data sets had been collected, the first order reaction rate was determined by 
plotting a graph of ln[amount of ADP produced] versus incubation time from the HPLC data 
and subsequently fitted to a straight line . A similar approach can be employed from the 
1
H 
NMR data from the integrated area (I) of a signal for a proton of interest at ta relative to that 
at t0, by plotting ln[Ia / I0] against reaction time ta. A second order rate relationship can be 
tested by plotting either 1/[ADP] or 1/[Ia / I0] versus reaction time, from either the HPLC or 
1
H NMR data, followed by line-fitting. 
1.1.8 Chemical structures proposing the effect of deuteration  
When a hydrogen atom in a given molecule has a higher electron density around its nucleus 
compared to neighbouring hydrogen atoms, it is termed a ‘shielded proton’ due to its 
possessing a stronger local magnetic field as a result; conversely, electron-density deficient 
hydrogen nuclei are referred to as ‘deshielded’ protons. As such, when a shielded proton’s 
apparent magnetic moment interacts with an applied external magnetic field, a reduced 
chemical shift occurs in the 
1
H NMR spectrum, compared to that produced by a deshielded 
proton. Deuterium-hydrogen exchange starts with the most deshielded protons in a molecule, 
mainly because these acidic protons require less energy for driving the deuteration process 
due to weaker C-H covalent bonds (Salisu et al., 2011). In Figure 1.4, aromatic protons are 
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depicted (see black arrows), as being the sites where the ATP molecules used in this study 
were deuterated, beginning at the C8 position, followed by the proton located at C2. 
 
Figure 1.4: ATP schematic diagram showing deuteration of ATP. Structure A is the  
protonated ATP molecule; structure B, the deuterated form of the ATP molecule. 
 
The protocol for determining that deuteration had taken place involved monitoring the 
1
H 
NMR spectrum of the reaction mixture for loss of intensity of the proton signals occurring 
between 8 and 6ppm. Due to the nature of proton NMR, this intensity is proportional to the 
number of protons represented by the signal. Thus, deuteration of these aromatic molecules in 
relation to the location of the relevant hydrogen signal(s) in the 
1
H NMR spectrum can be 
used to monitor based on the replacement of hydrogen by the deuterium atom, resulting in 
disappearance/reduction of the 
1
H NMR signal. Figure 1.5A represents the protonated ATP 
1
H NMR spectrum, while Figure 1.5B shows the effect of the deuteration process on the 
deshielded protons, as indicated by the black arrow. This 
1
H NMR spectrum should be 
viewed in conjunction with the structures in Figure 1.4A and B.  
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Figure 1.5: Schematic diagrams showing 
1
H NMR spectra, where A is a protonated ATP and  
B spectrum represents the deuterated ATP. Note the difference at 8.48ppm in both  
spectra (indicated by the arrows): in B the signal diminished as deuterium-proton  
exchange progressed. The other new proton signals in B resulted from the use of a 
catalyst in the reaction mixture, namely, trimethylamine. 
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1.1.9 High performance liquid chromatography (HPLC) 
High-performance liquid chromatography (formerly referred to as high-pressure liquid 
chromatography) HPLC, is a chromatographic technique used to separate, identify and 
subsequently to quantify components in a liquid sample mixture. HPLC in this sense can be 
used to provide both the qualitative and quantitative analysis of a dissolved sample’s 
molecular makeup. In this particular study, an automated Agilent 1100 HPLC instrument was 
used, employing a Kinetex 5µm C18 250 X4.6mm stationary phase column. The mobile 
phase (0.0515 M potassium dihydrogen phosphate and PIC reagent and 4.75M acetonitrile) 
interacting with sample adsorbed onto the solid phase of the column results in an affinity 
exchange chromatographic system. This allows for the separation of AMP, ADP and ATP in 
the mixture (Kenyon et al., 2011). Figure 1.6 is a schematic diagram showing how the 
analyte passes through the HPLC system for separation and characterisation. 
 
Figure 1.6: Schematic diagram of an HPLC, showing all of its components used to separate  
AMP, ADP and ATP from each other. 
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The pressure pump (HPP) drives the mobile phase from the solvent reservoir (RS) to the 
solvent injection port, where the sample solution is then injected into the system via the 
injection loop (SI). The sample is passed through the column (C), which is packed with 
stationary phase made up of material which is selected to chemically interact with the sample 
material. Such a chromatographic system results in differential retention of the various 
molecules in the sample suspension and their subsequent (differential) elution based on their 
specific solubility (affinity) for the mobile phase as compared to the stationary phase. 
For example, in an AMP, ADP and ATP mixture, the chemical interaction between stationary 
phase on this reversed phase column and the materials is in the order AMP > ADP> ATP, 
which is the observed elution order. In this manner, provided that the column packing 
material is correctly selected for system of interest, separation of the various molecules will 
be achieved. At the end of the column separation step, detection of molecules in the eluent is 
achieved by various kinds of detection systems based on UV/visible light, or a photodiode 
array (PDA), to name a few. In addition, where the desired focus is on separation of 
molecular ions present in a sample mix, known as mass spectrometry, both an ionising source 
needs to be in place at the point of sample injection, as well as a UV detector (D) being 
placed at the end of the system. 
During hydrogen-deuterium exchange on ATP molecules, some of the ATP is converted to 
ADP in the solution. HPLC protocols that were followed identified the ADP produced in the 
deuteration reaction (KENYON, Colin, 2007). Figure 1.7 shows a typical HPLC spectrum of 
the conversion of some ATP to ADP. In the top part of Figure 1.7, chromatogram (A) shows 
a pure ATP sample, while the middle chromatogram (B), shows both ADP and ATP signals. 
In chromatogram (C), hydrolysis of ATP can be seen on inspection, with lowering of the 
ATP signal compared to that of the blanked ATP (chromatogram A superimposed on B). 
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Figure 1.7: HPLC analysis of ATP. A is of pure ATP, B is of an enzyme-catalysed reaction  
showing partial hydrolysis to ADP, and C is an overlay of A and B. The arrows  
indicate the retention time of ADP. The two other two small peaks in the  
chromatogram are AMP and PPi, being considered not of particular  interest.   
1.1.10  Deuteration of purine- and imidazole-based compounds 
Purine- and imidazole-based compounds are five- and six-membered heterocyclic aromatic 
structures with several nitrogen atoms in their ring structure (Vianello, 2011). Aromatic 
properties of these kinds of molecules are contributed by electrons on the p-orbitals of the 
carbon and nitrogen atoms. A lone pair of electrons in the one nitrogen atom in imidazole and 
three nitrogen atoms in purines play a significant role in forming the π-bond to fulfil aromatic 
properties in the ring (Watson, Sweet, & Marsh, 1965) as proposed by Hückel's rule. The 
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purine molecule plays a significant role in biological synthesis of nucleic acids, by acting as 
an antitumor inhibitor (D’Auria, 2005); Koley et al., 2011). These heterocyclic rings are 
composed of sp
2
 hybridized carbon and nitrogen atoms, which allow the p-orbitals to form 
the conjugate system of π-electrons that delocalize around the ring system of the purine 
compound, as shown in right hand side of Figure 1.8. 
When π-electrons delocalize, leaving the nitrogen in a partially positive state, the molecule 
then becomes less reactive than other aromatic structures. In case of purines, the order of 
hydrogen-deuterium exchange is C2, C6 and C8, while in the case of imidazole structures, 
the order is C2 followed by C4 or C5 (Koley et al., 2011). Figure 1.8 C shows the imidazole 
numbering. Figure 1.8 D shows the lone pairs of electrons in the purine molecule.  
C
D
 
Figure 1.8: Chemical structure of imidazole C and purine molecule D showing the  
delocalising of π-bonded electrons and the numbering of the molecules.  
 
The hydrogen attached to nitrogen (N-H) in these molecules is highly labile, and is replaced 
immediately when the molecules are dissolved in deuterium oxide. In general, the proton 
NMR protocols used in this study were reliably able to confirm that deuteration of these 
molecules had taken place after comparing the 
1
H NMR spectrum of the native compound 
with its deuterated analogue. As was the case with ATP, proton signal intensities from both 
imidazole and purine were reduced or disappeared completely in the 
1
H NMR spectrum 
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following deuteration of these molecules (Giernoth & Bankmann, 2006). The resulting 
1
H 
NMR spectra (before and after deuteration) are given in Appendix Part one (p. 111-130). 
1.1.11 Substitution of 2,6-dichloropurine 
2,6-Dichloropurine contains two chloride atoms that are attached at positions 2 and 6 of the 
aromatic ring structure (Hocek &, Dvor'akov'a, 2003; Koley et al., 2011). Most literature 
suggests that purine molecules require more time and higher energy in order for the 
substitution to occur. The purine substitution is always in this order: 6, 2 and 8 (Koley et al., 
2011). Despite the many studies that have been conducted on purine or 2,6-dichloropurine 
synthesis, few have compared their inhibitory nature against enzyme activity, particularly 
when different substituting groups were attached to this purine. Research into purine 
molecules could reveal their importance as kinase inhibitors (Koley et al., 2011). The 
activities of any of the synthesized molecules in this class could potentially inhibit kinases 
and synthetases, possibly impacting on the management of diseases that would depend on 
being able to control the behaviour of these kinds of enzymes. In general, most of these types 
of molecules are hydrophobic, and so poorly bioavailable (Ogilvie et al., 1984). Set against 
this background, the current investigation was aimed at characterising the possible role 2,6-
dichloropurine might play in enzyme kinetic regulation. Modification of 2,6-dichloropurine 
was considered an ideal starting point, because the molecule has two positions for 
nucleophilic substitution. Position 6 is the first nucleophilic substitution favoured and it 
accounts for 67-70% of the reaction products, while position 2 only contributed 40-43% of 
isolated products (D’Auria, 2005). Figure 1.9 indicates how the three products can be formed 
when chlorine atoms in the 2 and 6 positions are respectively replaced with NH2 and protons. 
The three substituents that have been introduced are methyl, ethyl and benzyl; once each 
product was synthesised, it was tested for enzyme inhibition character.  
 33 
 
 
Figure 1. 9: Chemical synthetic scheme of 9-methylpurin-6-amine (A), 9 ethylpurin-6-amine  
(B) and 9-benzylpurin-6-amine (C) from 2,6-dichloro-9H purine. 
 
Using 
1
H NMR spectroscopy and thin layer chromatography (TLC), the presence of newly 
synthesized molecules was confirmed. 
1
H NMR identified the newly attached group by 
observing additional proton signals in the spectrum. 
 
The TLC confirmed the product’s formation based on retention factor (Rf) of starting material 
and its product. Both molecules (starting material and product) were loaded on aluminium-
backed silica TLC plates and eluted with solvent of 400mM ethyl acetate and 76mM hexane. 
Interactions with the stationary phase and the eluent allow the molecules to have a different 
Rf based on different adsorption character of each molecule in the solution. The Rf is the ratio 
of distance travelled by the sample (product or starting material), divided by the distance 
travelled by the solvent front. If the product has formed, the Rf  of the starting material and of 
its product will differ, but if the reaction has not occurred, the Rf will be identical under the 
same condition (Adler, Purich, & Stadtman, 1975). The bi-products synthetic purine 
compounds were named based on the eluted on size exclusion when there were separated. 
The compound that come out first in the column were named 1- purine compound while 
those come at the second were named 2- purine compound.  
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1.2   Materials and methods  
1.2.1 ATP, its deuterated analogue and their reaction rate determination  
A 20mM ATP (Roche diagnostic) water solution in 5ml sterile snap cap tube was prepared 
with an increasing percentage of deuterium oxide (D2O) (Sigma Aldrich) in four test tubes 
(25, 50, 75 and 100%) and labelled accordingly. A 69.3μl of triethylamine (TEA) (Sigma 
Aldrich) was added uniformly to all four 5ml sterile snap cap tubes to make 0.1mM TEA. In 
each test tube, a 0.10ml of reaction mixture was removed and introduced into a 0.5ml 
Eppendorf tube, closed and labelled as time zero and D2O%. This preparation was then stored 
at 4
o
C in a fridge for further analysis on both HPLC and NMR instruments. The remaining 
sample preparations in Eppendorf tubes were closed and incubated at 60
o
C on heating block. 
After every twenty four hour period, six 0.1ml amounts were removed from each reaction 
solution, placed in separate 0.5ml Eppendorf tubes and kept at 4
0
C for further analysis. 
For analysis of these samples, each 0.1 ml sample was split into two.  Firstly, Eppendorf 
tubes containing 0.05ml of 20mM ATP and dried in a vacuum concentrator (Savant SC110 
Speedy Vac) at 130rpm at 37
0
C in order to evaporate the TEA. Each of these preparations 
were then re-diluted with 0.45ml D2O and analysed by NMR to characterise both 1
st
 and 2
nd
 
order reaction kinetics. From the remaining amount of each sample preparation, a 0.045ml 
sample was taken and diluted with 0.41ml deionised  water or nano water, to make a 2.19mM 
solution for HPLC analysis and subsequent characterisation with respect to both 1
st
 and 2
nd
 
order reaction kinetics. 
1.2.2 Analysis of ATP and its deuterated analogue by NMR 
For 
1
H NMR analysis, 0.05ml of each sample prepared above was diluted with 0.45ml D2O, 
to make up a 2mM solution. This was added to an NMR tube and inserted into a Varian 
600Hz NMR, using 64 scans and a 2 second relaxation time at 30
0
C for data collection. 
Sample mixtures were analysed together with their time zero or blanked samples. The 
1
H 
NMR spectra thus generated were collected for calculation of rate order reaction kinetics 
using Graph Pad Prism software.  
1.2.3 Analysis of AMP, ADP and ATP by HPLC 
The remaining half (0.455ml) of each sample was dissolved in deionised water as described 
in Section 1.2.1, and then divided into triplicate samples (0.135ml in each vial) for HPLC 
analysis. The concentration of ADP produced and the amount of ATP left was measured from 
the resultant traces. Once the HPLC spectra data had been recorded, data was consolidated 
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using the GraphPad Prism 6 software, after which 1
st
 and 2
nd
 order reaction rate kinetics 
could be determined. 
1.2.4 Imidazole and purine deuteration analogues  
Commercial imidazole- or purine-containing samples were prepared at 100 mM 
concentrations in a 1.5ml Eppendorf tube, diluted with D2O and added to a 0.99mM 
triethylamine (TEA) solution. A 0.10ml blank sample was transferred to a 0.5ml Eppendorf 
tube before incubation and kept at 4
o
C in a fridge. The remaining solution was closed with an 
Eppendorf locker to prevent evaporation of TEA, incubated at 60
o
C on a heating block for 
three to five days. After the incubation period, 0.05ml samples of the 100mM solution were 
removed, placed in a 0.5ml Eppendorf tube and spun dried in a vacuum concentrator as 
before. This was diluted with 0.5ml D2O and inserted to 1.5ml Eppendorf tube and kept at 
4
o
C fridge for analysis. 
1.2.5 Analysis of imidazole and purine by 
1
H NMR 
The stored purine and imidazole samples were analysed by NMR. A 0.05ml sample of the 
100mM deuterated sample was diluted with 0.45ml D2O and analysed on a Varian 600Hz 
NMR to determine the 
1
H NMR spectra. The NMR was set to 64 scans and 2 seconds 
relaxation time at the room temperature. All the samples were prepared together with their 
time zero or blanked solution. The deuteration percentage was calculated from the integrated 
area of the substituted proton, divided by the sum of this integrated area, together with that of 
the neighbouring protons and multiplied by 100%. 
1.2.6 Synthesis of substituted purine molecules from 2, 6-Dichloropurine 
A 5,29mmol solution of 2,6-dichloropurine, 22,5ml acetone, and 10.58mmol sodium 
carbonate was prepared in a reaction vessel equipped with a reflux condenser. The mixture 
was boiled under reflux for 20min and then 5.29mmol iodomethane or ethyl bromide or 
bromobenzene was added in one portion. The reaction mixture was allowed to boil under 
reflux for 14 hours, after which the mixture was filtered through 0.4µm Whatman filter paper. 
The yellowish solution was concentrated in a rotary evaporator. The concentrate was purified 
through a column as follows: the silica columns were prepared and equilibrated with the 
mobile or elution solution of 4:1 (v/v) ethyl acetate: hexane solution. For the benzylbromide 
reaction, an elution gradient 3:2 (v/v) to 4:1 (v/v) ethyl acetate: hexane solution was used. 
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1.2.7 Separation of purine by-products by thin layer chromatography (TLC) 
The passage of all eluted samples was monitored by thin layer chromatography(TLC) and 
visualised using a 6W UV lamp (Hocek et al., 2003). With the same concentration of mobile 
phase solution, migration of the various components on the TLC plate allowed for subsequent 
grouping of by-product fractions in a repetitive manner using a rotor evaporator to remove 
the mobile phase and concentrate the product. 
This whole process was done in a repetitive manner, where drops of each sample were 
spotted on a TLC plate to determine each respective retention factor (Rf), using the original 
2,6-dichloropurine material on the left hand side of the plate. 
1.2.8 Recrystallization of purine by-products by dichloromethane: methanol 
Purine by-products were recrystallized by dissolving them in 7:3 (v/v) dichloromethane: 
methanol in a small beaker which was then sealed with parafilm. A small portion of each of 
these crystallised samples was analysed by 
1
H NMR (Watson, Sweet & Marsh, 1965). The 
remainder of each of the powdered samples were labelled, dated and kept at room 
temperature until required for testing for activity in an enzyme assay, to be elaborated on at a 
later point in this dissertation. 
1.3    Results 
1.3.1 Reaction rate order 
Both the 
1
H NMR and the HPLC spectral data were used to determine if first or second order 
reaction rate kinetics were operative. From the HPLC spectral data, the ADP concentration 
together with reaction time was used to prepare graphs of ln[ADP] or [ADP]
-1
 versus reaction 
time (in hours) to test for either first or second order reaction rate kinetics, respectively, with 
respect to ATP hydrolysis. In the case of the 
1
H NMR spectral data, three signals were 
considered of interest, all in the 6-9 ppm region of the spectra recorded. The proton signals 
are shown in the Figure 1.10 as (a), (b) and (c). The ratio of signal intensities (as Irel) was 
calculated using: 
Irel = Ia / (Ia + Ib + Ic) 
This was to normalise the intensities of the signals used internally. A graph of either ln[Irel] or 
[Irel]
-1
versus reaction time (in min) was constructed, in order to test for first or second order 
reaction rate kinetics, respectively, with respect to ATP C8 deuteration. 
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Figure 1.10: A 
1
H NMR spectrum of ATP showing the proton signals a, b and c used.  
1.3.2 Rate orders 
The following Tables (1.1-1.4) and Figures (1.11-1.14) reflect a systematic approach to 
hydrogen-deuterium exchange and subsequent testing for either first or second order kinetics 
for deuteration. The proton signal of interest is clearly seen in Figure 1.5 (p. 27), comparing 
the 
1
H NMR of ATP at top with that of deuterated ATP at the bottom. The most deshielded 
proton (indicated with a red arrow in the 
1
H NMR spectra of the deuterated material) 
disappears over time when compared to undeuterated ATP. 
The Appendix part two (p. 131-146) shows how ATP deuteration varies as a function of 
increasing concentration of deuterated solvent. These spectra show how the proton signals 
disappear as time and [D2O] increases at 60
o
C. From these 
1
H NMR data in Appendix part 
two (p. 131-146) the following Tables (1.1-1.4) and Figures (1.11-1.14) reflecting first and 
second order rate data were generated. 
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Table 1.1: First order rate constants for deuteration of ATP as a function of deuterium oxide  
concentration. 
 
Time / h 25% D2O 50% D2O 75% D2O 100% D2O 
0.00 -0.96 -0.96 -0.97 -0.95 
48.00 -1.00 -1.05 -1.13 -1.37 
72.00 -1.01 -1.09 -1.21 -1.76 
96.00 -1.05 -1.18 -1.34 -1.97 
120.00 -1.07 -1.21 -1.44 -2.23 
144.00 -1.18 -1.27 -1.57 -2.47 
 
 
Figure 1.11: Plot of lnIrel versus incubation time as a function of deuterium oxide  
concentration.  
 
 
 
 
 
 
 
 39 
 
Table 1.2: Second order rate constants for deuteration of ATP as a function of deuterium  
oxide concentration. 
 
Time / h 25% D2O 50% D2O 75% D2O 100% D2O 
0.00 2.62 2.62 2.63 2.60 
48.00 2.71 2.85 3.11 3.92 
72.00 2.74 2.98 3.37 5.79 
96.00 2.87 3.25 3.80 7.20 
120.00 2.91 3.35 4.20 9.33 
144.00 3.27 3.54 4.81 11.79 
 
 
Figure 1.12: Plot of Irel
-1
 versus incubation time as a function of deuterium oxide  
concentration. 
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Table 1.3: First order rate constants of ATP hydrolysis as a function of deuterium oxide  
concentration. 
 
Time / h 25% D2O 50% D2O 75% D2O 100% D2O 
0.00 0.00 0.00 0.00 0.00 
48.00 -2.67 -2.26 -1.96 -1.90 
72.00 -2.29 -1.86 -1.59 -1.50 
96.00 -1.88 -1.66 -1.15 -1.08 
120.00 -1.64 -1.39 -0.88 -0.82 
0.00 0.00 0.00 0.00 0.00 
 
 
Figure 1.13: Plot of ln ADP  versus incubation time as a function of deuterium oxide  
concentration. 
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Table 1.4: Second order rate constants of ATP hydrolysis as a function of deuterium oxide  
concentration. 
 
Time / h 25% D2O 50% D2O 75% D2O 100% D2O 
0.00 0.00 0.00 0.00 0.00 
48.00 14.42 9.62 7.10 6.66 
72.00 9.89 6.42 4.92 4.50 
96.00 6.58 5.27 3.15 2.96 
120.00 5.18 4.00 2.41 2.28 
144.00 4.62 3.16 1.97 1.87 
 
 
Figure 1.14: Plot of ADP]-1versus incubation time as a function of deuterium oxide  
concentration. 
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1.3.3 Deuteration of various imidazoles and purines 
The following Table 1.5 (p.44) and Figure 1.16 (p.45) show the percentage of deuteration of 
some imidazole- and purine-contaning compounds. The percentage was calculated as the 
ratio of Irel calculated as before at time tn with Irel at t0. An example showing how the 
calculation was performed is shown using Figure A.1.17 in the Appendix part one (p.118).  
That figure is repeated here as Figure 1.15. 
In Figure 1.15, the protonated (A) and deuterated (B) NMR spectra of 1-ethylimidazole with 
the proton signals a, b and c used in the calculation are shown. Here, a is the proton signal 
that was reduced by deuteration, b and c are reference or neighbouring proton signals in this 
molecule. 
 
 
Figure 1.15:  
1
H NMR spectrum of 1-ethylimidazole, before (A) and after (B) deuteration.  
The proton replaced by deuterium is shown by a black arrow in A, and its position by  
a red arrow in B. 
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In this example, the integrated intensities used for t0 from spectrum A are: Ia = 2.37, Ib = 3.27 
and Ic = 3.21 
Irel at t0 for spectrum A is given by: 
  Irel(t0) = Ia(t0)/ [Ia(t0)+ Ib(t0)+ Ic(t0)]  
  = 2.37/ (2.37+3.27+3.21) 
  = 0.27 
Irel at tn for spectrum B is given by: 
  Irel(tn) = Ia(tn)/ [Ia(tn)+ Ib(tn)+ Ic(tn)] 
   = 0.00 / (0.00 + 0.23 + 0.19) 
  = 0.00 
So, the degree of deuteration = 100{1- [Irel(tn) / Irel(t0)]}= 100{1 - [0 / 0.268]} = 100%. 
Using a similar calculation, the deuteration percentages were calculated for all the purine and 
imidazole compounds (see Tables and Figure in Appendix part one (p. 111-130). Note that 
the position of deuteration is structure-dependant. 
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Table 1.5: Percentage of proton-deuterium exchange in several 100µM purine and imidazole  
systems. All the compounds were deuterated by incubation at 60 
0
C for 5 days before  
analysis with 
1
H NMR. 
 
Name of compound Figure number in 
appendix 
% Deuterium 
substituted 
Adenine Figure A.1.14 43.41 
2-Iodoadenosine Figure A.1.10 79.00 
6-Benzylaminopurine Figure A.1.6 70.00 
Benzimidazole Figure A.1.2 100.00 
5-Methyl-4-nitroimidazole Figure A.1.40 38.79 
1-(3-Aminopropyl)imidazole Figure A.1.30 100.00 
4-Imidazolecarboxaldehyde Figure A.1.26 100.00 
1-Butylimidazole Figure A.1.28 100.00 
4(5)-Methylimidazole Figure A.1.22 100.00 
1-Ethylimidazole Figure A.1.16 100.00 
1(3)-Methylimidazole Figure A.1.18 100.00 
4-Imidazolecarboxylic acid Figure A.1.24 100.00 
4(5)-Hydroxymethylimidazole Figure A.1.20 100.00 
5-Chloro-1-methylimidazole Figure A.1.38 100.00 
2,6-Diaminopurine Figure A.1.8 100.00 
4,5-Dicyanoimidazole Figure A.1.36 19.29 
4-Nitroimidazole Figure A.1.34 100.00 
4-Azobenzimidazole Figure A.1.12 65.12 
1-Vinylimidazole Figure A.1.32 100.00 
1-Methylbenzimidazole Figure A.1.4 100.00 
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Figure 1.16: Hydrogen-deuterium exchange as a percentage of deuteration for various  
imidazole- or purine-based compounds (see appendix part one (p. 111-130)). 
1.3.4 Synthetic substituted purines 
Figure 1.17 shows the reaction mixtures using 2,6-dichloropurine as starting material 
separated on silica thin layer chromatography (TLC). On left-hand side is 2,6-dichloropurine 
(Rf 0.37), followed by the products 9-methylpurin-6-amine (Rf 0.51 and Rf 0.39), 
9-ethylpurin-6-amine (Rf 0.73 and Rf 0.57) and 9-benzylpurin-6-amine (Rf  0.70 and Rf 0.79). 
The solvent front is indicated with a purple line in the Figure 1.17. 
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Solvent in front
 
Figure 1.17: TLC plate showing the different Rf values of three products synthesised from  
2,6-dichloropurine. 
1.3.5 Discussion 
The study done on 
1
H NMR confirms that the rate of ATP deuteration at C8 depends on the 
concentration of deuterium  oxide (D2O) and ATP, as well as the incubation period at 60
o
C  
(Heller, 1968). When the temperature was kept constant, the deuterium-proton exchange 
increases as the [D2O] increases. As the deuteration increased, the ATP hydrolysis also 
increased, although not at the same rate. When the reaction was inspected by the reaction rate 
order method of Faizi et al., 2010 in Figures 1.11-1.14 (p.38-41), it was clear that ATP 
hydrolysis was a first order reaction in [D2O] because Figure 1.14 did not form a straight 
line. The deuteration could be either 1
st
 or 2
nd
 order, as was shown in Figures 1.11 and 1.12, 
with nearly a straight line being formed in both instances. 
The study also determined that hydrogen-deuterium exchange is not kinetically identical to 
ATP hydrolysis under the same conditions. The reaction rate order method supported that 
ATP C-8 deuteration was second order in both [ATP] and [D2O]. The 
1
H NMR spectrum also 
showed that the C-8 proton of the ADP thus formed is also deuterated in the process. 
 47 
 
As indicated in the introduction, protons with successively higher acidity would sequentially 
be substituted with deuterium under these conditions. The 
1
H NMR spectra of ATP showed 
that hydrogen/deuterium replacement began with the hydrogen located on 8ppm on the 
1
H 
NMR spectrum, being the most acidic or deshielded of the protons in the ATP molecule. 
Once the hydrogen located in that position in molecule was fully deuterated, the second 
which is quarter deuterated, the proton/deuterium replacement took place on the next 
(second) de-shielded proton, which was located at 7.3ppm of 
1
H NMR spectra while the third 
becoming partially deuterated. However, this replacement took a relatively longer time, 
reflecting its poorer reactivity compared to the first proton. As [D2O] increased in the 
solution, the chance of intermolecular encounters increased, with a higher level of deuteration 
being observed with 100% D2O using 20mM ATP as seen in Figures 1.11 and 1.12. This 
result is also apparent in the data of the Appendix Part two Figure B.1.1- B.1.28 (p.137 to 
146). As previously indicated, the higher availability of deuterium in the solution assisted in 
proton/deuterium substitution, particularly at a higher [D2O] when compared to the lower 
[D2O] in solution. 
The deuteration of imidazole- and purine-based molecules was found to occur in high yield, 
with more than 80% of the compounds being found to be >70% deuterated, as was apparent 
from Figure 1.16 (p.45). Where deuteration of ATP was concerned, for the entire compound, 
the exchange was found to take place at the most deshielded location on the 
1
H NMR 
spectrum as before.  
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CHAPTER 2: THE KINETIC ISOTOPE EFFECT (KIE) IN ACETATE KINASE, 
SHIKIMATE KINASE AND GLUTAMINE SYNTHETASE IN THE PRESENCE 
OF ATP OR ATP-D 
INTRODUCTION 
The enzymes acetate kinase, shikimate kinase and glutamine synthetase all catalyse the 
hydrolysis of ATP to produce ADP or AMP. Energy stored in ATP is released upon 
hydrolysis of the phosphoric anhydride bonds. The primary phosphate group on the ATP 
molecule that is hydrolysed when energy is needed to drive anabolic reactions is the γ-
phosphate group. Located the farthest from the ribose sugar, it has a higher energy of 
hydrolysis than either α- or β-phosphates. The bonds formed after the phosphorylation of a 
substrate residue by ATP are lower in energy than the phosphoric anhydride bonds of ATP. 
During enzyme-catalysed hydrolysis of ATP, or phosphorylation by ATP, the available free 
energy can be harnessed by a living system to do work. This chapter deals with the chemical 
structure of ATP, the role of the adenyl moiety in the phosphorylation reaction mediated by 
ATP in all three enzymes, as well as the importance of these enzymes in various aspects of 
biological chemistry. From a kinetic / mechanistic point of view, the reaction proceeds as 
follows: 
E + S ↔ ES ↔ ESP → E + P 
where E is the enzyme involved, S is the substrate and P is the product of the reaction. 
Initially the enzyme (E) combines with the substrate (S) and form an intermediate complex 
(ES). The enzyme then partially converts some of the substrate to yield another intermediate 
that now includes some of the product as part of the intermediate complex. This is not a 
simple process, with the mechanism depending on many factors, including pH, the 
concentration of the reactants and products, incubation period and also temperature. This part 
of the study focuses on specific activity of the enzymes together with the kinetic isotope 
effect (KIE), which is used to compare ATP and its deuterated analogue as co-substrates for 
some selected enzymes. Graph Pad Prism 6 software was used to analyse for a KIE in 
enzyme co-substrate reactions, before and after deuteration of the co-substrate, specifically 
focussing on the behaviour of ATP-dependant enzymes. 
2.1    Acetate kinase (AK) 
Acetate kinase (AK) was discovered in 1944 by Lipmann and first isolated in 1954 by Ochoa 
(Buss et al., 2001). The enzyme is a prototypic carboxylate kinase and is one of the earliest 
recognized phosphoryl transfer enzymes (Buss et al., 2001). AK is found in aerobic as well as 
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anaerobic microorganisms, archaea, fungi and mammals. It plays a major role in global 
cycling of carbon by anaerobic decomposition of organic matter to methane (Schmidt, Biegel, 
& Müller, 2009). AK catalyses the transfer of the phosphoryl moiety from ATP, to the 
carboxylate group of acetate to form acetyl phosphate and ADP. The reaction is shown in 
Figure 2.1 (Mukhopadhyay, Hasson, & Sanders, 2008):  
ATP + Sodium acetate + Mg
2+
 ↔ ADP + acetyl phosphate + Mg2+ 
 
Figure 2.1: Acetate kinase catalyses the reaction between acetate and ATP to produce acetyl  
phosphate and ADP or AMP (Mukhopadhyay et al., 2008). 
 
The enzyme is central to carbon and energy metabolism and has been demonstrated to be a 
member of ASKHA (Acetate and sugar kinase Hsp70, actin), a phosphotransferase super 
family (Kenyon et al., 2011; Mukhopadhyay et al., 2008; Scapin, 2002). Together with 
acetyl-coenzyme A (Acetyl-CoA), AK is a key bacterial synthetic enzyme. Synthesis of 
acetyl phosphate is an important biosynthetic product that is converted to Acetyl-CoA by 
phosphotransacetylase (PTA) according to: 
Acetyl-phosphate + CoA + PTA ↔ Acetyl-CoA + Pi 
It is also a potential regulator of bacterial signal-transduction (Buss et al., 2001). Figure 2.2 
shows example of the structure of an AK enzyme, whose structure can be likened to that of a 
hamburger, i.e. two halves of a bun enclosing an ATP ‘patty’. The upper ‘bun’ in blue (left 
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upper black arrow) represents the N-terminal part of the complex, while the red ribbon (left 
lower arrow) forms the lower ‘bun’, or C-terminal part of the structure. The ATP molecule 
(right middle arrow – space-filling model) is shown ’sandwiched’ between the C-terminal 
and the N-terminal ends, forming the ‘hamburger patty’ in the Figure 2.2. This site between 
the two ‘buns’ binds ATP or its deuterated analogues, and is the focus of the present 
investigation that will be discussed at length in the next section.  
 
Figure 2.2: Crystal structure of (bone marrow kinase) an example of acetate kinase with the  
N-terminus in blue (upper left arrow), and the C terminus in red (lower left arrow).  
ATP is shown in the binding cleft as a space-filling model (middle right arrow)  
(Muckelbauer et al., 2011). 
2.1.1 ATP complexes with acetate kinase                                                    
Previous studies done on the interaction of ATP with kinases has revealed that this interaction 
is most likely governed by the structure of both ATP and the enzyme. The resultant complex 
formation is believed to play an important role in enzyme activity. In particular, the adenine 
moiety of ATP binds in the hydrophobic pocket of AK formed from residues Val57, Leu49, 
Ala70, Meth120 and Tyr122 on a β-sheet (Ingram-Smith et al., 2005). The adenine moiety is 
anchored via a hydrogen bond to the select group of amino acids in the ATP binding pocket 
of AK. The existence of this hydrogen bond is important, because if the hydrogen bonding 
group is replaced with a hydroxyl group, the level of enzyme activity is diminished (Zheng et 
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al., 1993); Suwal et al., 2012). Additionally, the ribose sugar is hydrogen-bonded through the 
2'-OH, while all the ATP phosphates project towards the loop and interact with residues from 
both domains. The α- and β-phosphates then interact with Lys72 in the β-strand and Glu91 in 
the α-helix. 
 
The γ-phosphate extends towards the solvent-accessible region of the binding site, and is 
hydrophilic. In this manner, both enzyme and ATP adenine structure facilitate the transfer of 
the γ-phosphate to the hydroxyl group of the amino acids of a particular substrate (Gorrell et 
al., 2005). AK thus forms an interaction pocket, allowing the γ-phosphate group to function 
as part of a catalytic cycle that includes a hydroxyl group of the target co-substrate (Gorrell et 
al., 2005). The metal ion (Mg
2+) coordinates to the α- and β-phosphate groups through their 
oxygen atoms, helping to position the γ-phosphate correctly with respect to this co-substrate 
hydroxyl group (Ingram-Smith et al., 2005). The enzyme facilitates the transfer of 
γ-phosphate to carboxylate of acetate to produce acetyl phosphate and ADP (Gorrell et al., 
2005; Mukhopadhyay et al., 2008).  
2.2   Shikimate kinase (SK) 
Shikimate kinase is the fifth enzyme in the shikimate pathway. SK specifically catalyses the 
reversible transfer of γ-phosphate from ATP to the 3-hydroxyl group of shikimic acid to yield 
shikimate 3-phosphate and ADP. The reaction is shown schematically in Figure 2.3 (Cheng, 
Chang & Wang, 2005; Pereira et al., 2004). The reaction is as follows: 
ATP + Shikimate + Mg
2+
 ↔ Shikimate 3-phosphate + ADP 
There are two isoforms of shikimate enzyme: SK-I and SK-II: both share 30% homology of 
their DNA sequences (Krell, Coggins & Lapthorn, 1998). This study uses SK-II, which is 
involved in the synthesis of chorismate. 
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Figure 2.3: Shikimate kinase catalyses the conversion of shikimate to shikimate 3-phosphate  
while ATP is hydrolysed to ADP or AMP (Daugherty et al., 2001). 
 
The role played by SK-II in synthesizing chorismate is particularly relevant to combating 
infections caused by pathogens such as Mycobacterium tuberculosis, which requires SK-II 
for the maintenance of biochemical pathways, including the synthesis of chorismate 
(Daugherty et al., 2001). In general, SKs have become a target for synthesis of antimicrobial 
and herbicidal agents (Krell, Coggins & Lapthorn, 1998) mainly because of co-infection with 
human immunodeficiency virus (HIV) in individuals also infected with tuberculosis (TB) 
(Reichau et al., 2011). The resultant increase in mortality in certain sectors of the South 
African population, particularly in the Western Cape, makes finding effective ways to combat 
these ailments a crucial task for improving the future health of this society. While many 
studies have been conducted for potential inhibitors of enzyme activity of various pathogens 
(Kumar et al., 2010), very few were designed to compare activity of their equivalent 
deuterated analogues as potential inhibitors (Vonrhein, Schlauderer  & Schulz, 1995). 
The shikimate kinase enzyme consists of five -strands in the order of β2, β3, β1, β4 and β5 
surrounded by -helices (Figure 2.4 A&B). These -strands are separated from one another 
on either side by α-helices. When the linkage of the structure is viewed from the N-terminal 
to the C-terminal end, the series of α-helices are as follows: α1 and α8 on one side α4, α5 and 
α7 on the other crosswise, as seen on the Figure 2.4B ( Krell, Coggins & Lapthorn, 1998). 
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This particular study uses a shikimate kinase enzyme from Mycobacterium tuberculosis 
(MtSK), which is classified under the kinase family of nucleoside monophosphate kinases. 
All nucleoside monophosphate kinases have five -strands occurring parallel to each other to 
form the active site ( Filgueira de Azevedo et al., 2002; Kenyon et al., 2011). In general, 
enzymes of this type have four domains based on changes occurring when ATP binds to the 
reactive site. These domains are: the shikimate binding (SB) domain, LID domain, nucleotide 
binding (NB) domain and reduced core domains (Figure 2.4B, (Krell, Coggins & Lapthorn, 
1998). 
 
Figure 2.4: A: 3D structure of shikimate kinase with ADP and shikimate bound in their  
respective sites. -strands are indicated in red, and α-helices in green, with the  
position of the Mg
2+
  ion in dark blue; B: schematic representation of the linkage of  
α-helices and β-sheets in the enzyme (A: Pereira et al., 2004; Krell, Coggins & 
Lapthorn, 1998). 
2.2.1 Reactions taking place in the active site of  MtSK 
Referring to Figure 2.4 in A, the adenine moiety of ATP is held in between the Arg110 and 
Pro155, while the LID domain loop interacts with the γ-phosphate during the catalysis step of 
the reaction. Arg117 binds with the α- and β-phosphates and water to stabilise the transition 
state created by the negative charge on the oxygen atom from the α-β bridge. The six-
coordinate bond of Mg
2+ 
ion is disrupted by attachment of the shikimate to form the Mg
2+
-
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MtSK-ADP-shikimate complex. The Mg
2+
 ion in this intermediate forms a complex with the 
β-phosphate oxygen of ADP, four water molecules and Asp34 (Pereira et al., 2004). 
2.3 Glutamine synthetase (GS) 
Glutamine synthetase (GS) is found in prokaryotes, plants and animals, and plays an essential 
role in the nitrogen metabolism of all living organisms (Occhipinti et al., 2010). In E. coli, 
the enzyme has a molecular weight of 600 kDa and is composed of 12 identical subunits that 
are arranged in two superimposed hexagonal rings (Bodasing et al., 1985; Stadtman., 2001). 
This enzyme, due to its shape, is referred to as a snowflake molecule, and is principally active 
when the cell experiences nitrogen-limiting conditions. GS activation is modulated by 
covalent attachment of one adenosine monophosphate group to each subunit of the structure 
(known as adenylylation). GS catalyses the reversible conversion of L-glutamic acid to L-
glutamine using ATP, as shown in Figure 2.5 (Stadtman, 2001):  
Glutamate + NH3 + ATP + Mg
2+  Glutamine + ADP + Mg2+ 
The GS catalyses the attachment of γ-phosphate atom from ATP to the glutamate, forming 
glutamyl-phosphate in the presence of ammonia, is converted into glutamine (Krajewski et 
al.,2008).  
 
 
Figure 2.5: Glutamine synthetase converts glutamate to glutamine by phosphorylation ATP  
to a γ-glutamyl phosphate intermediate. The γ-glutamyl phosphate intermediate is  
converted to glutamine via nucleophilic attack by ammonia  
(http://themedicalbiochemistrypage.org/nitrogen-metabolism.php). 
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The active site is found in between the intra-ring subunits. Ammonia and ATP enter via a 
channel at the interface between the rings (Figure 2.6 A and B) (Wray & Fisher, 2010). A 
metal ion in the active site helps to properly orientate ATP, ammonia and glutamate (Figure 
2.6 A). The GS enzyme exists in either adenylylated or deadenylylated form (Ronzio, Rowe 
& Meister, 1969; Stadtman, 2001; Ferguson and Sims, 1974 ).  
 
Figure 2.6: A: Hexameric structure of GS with bound ATP/ADP (black stick, indicated by the 
Arrow). The beta- sheets of various monomers are marked in orange or blue lines. B: 
ATP/ADP binding site with a glutamate mimic (methionine sulfoximine or metsox, 
indicated as MSO-P), ADP and three Mg
2+
 ions (indicated by the arrow) bound 
(Krajewski, Jones & Mowbray, 2005; Krajewski et al., 2008). 
As previously mentioned, GS is found in both plants and animals, where it catalyzes the 
ATP-dependent formation of glutamine from glutamate (Zozaya-Hinchliffe et al., 2005; 
Eisenberg et al., 2000). GS in plants and animals does not undergo the adenylylation/ 
deadenylylation cascade, which is typical of prokaryotic organisms. However, in the majority 
of plants, the GS enzyme pairs with glutamate synthase to deaminate the product glutamine 
and form two molecules of glutamate (Occhipinti et al., 2010). Plant GS occurs in two forms, 
GS1 and GS2, based on subcellular location (Cullimore & Sims, 1981). GS1 is located in the 
cytoplasmic matrix, while GS2 is found in the plastids of plant cells (Simonović & Anderson, 
2008; Occhipinti et al., 2010). 
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2.4   Commonalities between shikimate kinase, glutamate kinase and acetate 
kinase  
Shikimate kinase, acetate kinase and glutamine synthetase all have commonalties with the 
transferral of the γ-phosphate from ATP to the carboxyl group of the co-substrate, resulting in 
the formation of ADP or AMP, together with a new phosphorylated co-substrate.  
2.5    Kinetic isotope effect resulting from selective deuteration of substrate of 
an enzyme 
The Kinetic Isotope Effect (KIE), in the present context, refers to the ratio of the reaction 
rates determined from the reaction with a fully protonated molecule, relative to its 
counterpart, that has been selectively deuterated at a mechanistically active position (Wade, 
1999), i.e.: 
KIE = KH / KD 
As such, the deuterated substrate molecule ends up with higher molar mass, due to a doubling 
of the mass of the labile (and mechanistically relevant) proton (Hennig, Oswald & Schmatz, 
2006). Further, the C-D (deuterium) bond is shorter and stronger than the equivalent C-H 
bond (Wade, 1999). This causes changes in the enzyme catalysis reaction itself (Vigano et 
al., 2004), giving rise to anomalies resulting from mass defects in the enzymatic reaction, that 
are identifiable using kinetic analysis. The binding energy of the reaction may also be 
affected by the deuteration process (Sen & Kohen, 2010). 
2.6    Materials and methods 
2.6.1 Acetate kinase assays 
Acetate kinase was purchased from Sigma-Aldrich. A stock solution of 0.0005U/ml was 
prepared in deionised water and stored at -20
o
C until required. 
2.6.1.1   Acetate kinase time assays 
Each assay contained 26.67mM Trizma-HCl pH 6.8, 3.667mM sodium acetate, 0.034mM 
MgCl2, and 0.4mM ATP in a 5ml test tube. All the reagents were in the tube prior to addition 
of the enzyme, which was stored in an Eppendorf tube in an ice cooler box. For each reaction 
mixture, a time zero sample was taken prior the addition of the enzyme. Following addition 
of the enzyme, the solution in each of a series of tubes was quickly mixed and placed in a 
37
o
C incubator. Thereafter, a 350μl aliquot of the reaction mixture was removed from each 
vessel at 15, 30, 60, 120, 180, and 240 min after enzyme addition and transferred to a 1.5ml 
Eppendorf tube. Each aliquot was treated with 3µl of 63mM trichloroacetic acid (TCA) to 
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denature the protein, and the resulting solids removed by pelleting with a bench top 
centrifuge. After carefully labelling of the aliquots according to incubation time, the materials 
were stored on ice for later analysis. The mixtures were divided into 110µl triplicates, loaded 
into HPLC vials and analysed by HPLC to determine amount of ADP produced as a function 
of incubation time. 
 
2.6.1.2   Acetate kinase ATP or ATP-d concentration assay  
Each assay contained 26.67mM Trizma-HCl pH 6.8, 3.667mM sodium acetate, 0.034mM 
MgCl2, 0.0005U/ml acetate kinase in a 1.5ml test tube. The effect of ATP or ATP-d 
concentration was determined over a range of concentrations (200, 400, 600, 800, 1000, 1200 
and 1400 µM) (Kenyon et al., 2011). The reactions were prepared without enzyme and 
incubated at 37
o
C for five min before addition of 924µl in 10ml volume of 0.0005U/ml 
enzyme stock solution, except for each blank which did not contain enzyme. Reactions were 
terminated after 30min with an addition of 2µl of 63mM of Trichloroacetic acid (TCA) and 
immediately centrifuged. The AMP, ADP, ATP concentrations were determined by HPLC. 
All enzyme activities were expressed as specific activities [(µmole ADP formed).min
-1
. (mg 
protein)
-1
]. The kinetics of the enzymes was determined using Graph Pad Prism software. 
 
2.6.2 Shikimate kinase  
Shikimate kinase was cultured, purified and isolated from a recombinant Escherichia coli 
production strain which contained an expression vector including the gene coding for SK, 
obtained from the laboratory of Chris Abell, University of Cambridge. SK was cloned and 
purified using the following method: E. coli was used as a vector because it is a cheap, 
manageable, well-studied bacterium capable of producing both types of SK; however, the 
SK-II is the most active isoform in this bacterium. 
2.6.2.1   Insertion of the SK-encoding gene into an E. coli system  
Plasmid pBAN0209 containing the M. tuberculosis aroK gene encoding MtSK, was supplied 
by the laboratory of Chris Abell, University of Cambridge. pBAN0209 consists of the aroK 
gene cloned into the pET15b (Novagen) system, resulting in the IPTG-inducible expression 
of an enzyme containing the N-terminal 6-His purification tag, as indicated in the vector 
diagram in Figure 2.7 (Rosado et al., 2013) 
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pBAN0209
6231bp
T7p
6His  tag
aroKAmpR
lacI
ClaI (24) HindIII (29)
BamHI (319)
Ps tI (359)
XmaI (388)
SmaI (390)
NcoI (912)
ApaLI (1719)
ApaLI (4157)
ApaLI (4657)
Ps tI (5481)
ApaLI (5903)
EcoRI (6229)
NdeI (854)
 
Figure 2.7: Diagrammatic representation of a vector containing the aroK gene for use in an  
E. coli expression system.  
 
2.6.2.2   MtSK Expression and Purification 
E. coli BL21(DE3) competent cells were transformed with the pBAN0209 vector for 
subsequent IPTG-induced gene expression. Single colonies were selected for inoculation into 
50ml LM + Amp100 (liquid medium containing 5g of NaCl, 10g of yeast extract,10 of 
tryptone +100 µg/ml ampicillin) and cultivated overnight at 37°C, after which 2.5ml of this 
culture was transferred to 250ml of the same medium. Cultivation continued until OD600  
0.5-0.8 was recorded on a PerkinElmer lambda 35 UV/VIS spectrometer. 250µl 1M IPTG 
(Isopropyl β-D-1-thiogalactopyranoside) was added for induction of gene expression under 
control of the T7lac promoter and the culture was grown at 30°C overnight. 
The biomass from a 250ml culture flask was harvested, re-suspended in 20ml Binding Buffer 
(500mM NaCl, 40mM Tris, 5 mM imidazole pH 7.9) and sonicated for 20min on a 50% on-
off cycle. The sonicated mixture was then centrifuged at 10000rpm in an SS34 rotor for 
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10min at 4°C, after which the supernatant was clarified through a 0.45 µm syringe filter and 
loaded onto the Bio-Rad Profinia Protein Purification System. Analysis of the different 
fractions from the purification was carried out using an 11% SDS-PAGE system (Vonrhein, 
Schlauderer, & Schulz, 1995) that indicated the presence of a major band in the 28kDa range 
(Figure 2.8). 
 
Figure 2. 8: An SDS-PAGE gel comparing the migration of the purified sample of shikimate  
 kinase. The molecular weight marker is in the first lane (sizes in kDa on the left)  
 followed by the filtrate loaded onto the Profinia column, the flowthrough, two wash  
 steps, then the eluate in the last lane, containing the MtSK protein (indicated by the  
 arrow). 
 
Dialysis of the eluted protein was carried out overnight at 4°C using Pierce Snakeskin 
Dialysis tubing with a 10 kDa Molecular Weight Cut-Off (MWCO), in Dialysis Buffer 
(50mM Tris pH 7.5, 1M NaCl) (Rosado et al., 2013; Vonrhein et al., 1995). Aliquots of the 
dialysed enzyme were snap-frozen in liquid nitrogen and stored at -75°C until needed. When 
required, shikimate kinase concentration was determined by Qubit® 2.0 Fluorometer. 
2.6.2.3   Time assay analysis by shikimate kinase (MtSK) 
The stored MtSK was diluted with deionised water to make a 0.0001U/ml stock solution and 
stored at -72
o
C until needed. The SK time assay contained a solution made up of 100mM 
KH2PO4/K2HPO4 (pH 6.8), 0.02mM MgCl2, 0.2mM ATP, 10mM KCl and 2mM shikimic 
acid. A 750µl of the diluted 0.0001U/ml MtSK was added to 5ml of this stock solution, 
 60 
 
initially kept at 4
o
C, and the mixture was then vortexed and transferred to a 37
o
C ProBlot
TM
 
Jr Oven. A series of 350μl aliquots were taken at 0, 30, 60, 90, 120 and 180min and 
transferred to 500μl Eppendorf tubes. The reaction in each tube was then terminated by 
addition and subsequent vortexing with 2µl of a 5.7mM EDTA stopping reagent. 110μl 
amount of each terminated reaction was then transferred into HPLC vials, in triplicate and 
analysed. Once HPLC spectra were generated, the data for each reaction was recorded and 
reworked using Graph Pad Prism software in order to plot time specific activity graphs.  
2.6.2.4   Shikimate kinase stability assay 
Two different assays were performed, namely time assays and stability assays. In the time 
assay described in the previous section, the reaction mixture was incubated at 37
o
C, and at 
each time interval a sample was taken for analysis. With the stability assay, the reaction 
mixture was kept at 4
o
C for each time interval, after which a 350µl aliquot was removed from 
the sample mixture, incubated at 37
o
C for 20min, after which the reaction was stopped and 
analysed. The stability assay contained 100mM KH2PO4/K2HPO4 pH 6.8, 0.02mM MgCl2, 
0.4mM ATP, 10mM KCl and 2mM shikimic acid. A 750µl of diluted MtSk (1.73µg/ml)  was 
added in a 5ml reaction test tube, which contained the reaction mixture kept at 4
o
C, after 
which vortexing took place. The reaction mixture was kept at 4°C. Thereafter, a series of 
350µl amounts, at time intervals of 15, 30, 60, 90,120 and 180min, were removed and 
transferred to 500ul Eppendorf tubes, which were incubated at 37
o
C for 20min. Each reaction 
was subsequently stopped by adding 2µl of a 200mM EDTA to each reaction tube, followed 
by centrifugation at 13000rpm for 2min. An amount of 110µl of each terminated reaction was 
then transferred HPLC vials in triplicate, to determine the AMP, ADP, ATP formation. Once 
HPLC spectra were generated, the data for each reaction was recorded and reworked using 
Graph Pad Prism 6 software in order to plot enzyme activity graphs. 
2.6.2.5 The shikimate kinase ATP or ATP-d concentration assays 
The assay contained 100mM KH2PO4/K2HPO4 pH 6.8, 0.020mM MgCl2, 10mM KCl and 
2mM shikimic acid and a concentration series of 200 - 1200µM ATP or ATP-d in 500µl 
Eppendorf microfuge tubes. MtSK was diluted to 1.73µg/ml by diluting 75µl of MtSK 
enzyme to 500µl of stock solution in each tube at 4
o
C.  A blank was removed from each 
ATP/ATP-d reaction mixture prior to the additional of enzyme. The reactions were incubated 
at 37
o
C for 20min. After incubation, all reactions were stopped with the addition of 2µl of 
200mM EDTA. All samples were analysed in 110µl triplicate amounts aliquotted into HPLC 
vials to determine the amount of ADP formed. The data obtained from HPLC was used to 
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plot specific activity as well as KIE of ADP formation against the ATP or ATP-d 
concentration, by using graph on Graph Pad Prism software. 
2.7    Glutamine synthetase assays 
2.7.1 Deadenylylated GS concentration assays 
The deadenylylated GS assays were prepared in 1.5ml Eppendorf tubes kept at 4
o
C in 0.5ml 
reaction vessels as follows: 4mM sodium glutamine, 4mM NH4Cl, 0.022mM MgCl2, 
ATP/ATP-d solutions in a 200µM - 3000µM concentration series, 20mM imidazole (pH 7.3), 
0.003U/ml deadenylylated GS. The components were mixed quickly. A 110µl aliquot was 
taken as a blank sample, to which 0.95µl of a 100% TCA stopping solution was immediately 
added. The remaining reaction mixture was then placed in a 37
o
C incubator for 30min. At the 
end of 30min period, 2.85µl of 100% TCA stopping reagent was added to the mixture and 
mixed, followed by centrifugation at 3000rpm for 2min. The solutions were loaded in HPLC 
vials in triplicate, for determining the amount of ADP formed. The collected data on HPLC 
was the plotted as specific activities versus the ATP concentration, with the aid of Graph Pad 
Prism 6 software. 
2.8 Results and discussion: KIE for AK, SK and GS using ATP and ATP-d 
2.8.1 Acetate kinase 
Time assays were performed on acetate kinase to select the optimal incubation period for 
subsequent assays in the study. The results obtained are summarised in Table 2.1 and Figure 
2.9 below. 
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Table 2.1: Acetate kinase specific activity as a function of incubation time. Constant enzyme  
and ATP concentration was used (n =3). 
Time / min 
Av. specific activity / μM 
ADP.(mg protein)
-1
.(min)
-1
 
sd / μM 
ADP.(mg protein)
-1
.(min)
-1
 
0.00 0.00 0.00 
10.00 34136.95 416.94 
20.00 51274.17 223.89 
40.00 67487.94 1221.54 
80.00 87363.14 2944.72 
120.00 99731.91 4500.64 
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Figure 2.9: Specific activity of AK versus increasing time at constant ATP and acetate kinase  
concentration. The linearity is found between the two arrows. 
 
The incubation period was selected in the initial linear phase before the enzyme reached 
equilibrium. For acetate kinase, the optimal time was found to be 25 ± 3min, as indicated 
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with the arrows on Figure 2.9. With this information on hand, attention was placed on  AK in 
ATP or ATP-d competition assays, with equimolar concentrations of these species present for 
the purposes of KIE analysis. These data are presented in Table 2.2 and Figure 2.10. 
 
Table 2.2: Specific activity of acetate kinase as a function of stepwise increases in  
concentration of a 1:1 (ATP: ATP-d )reaction mixture under constant incubation time  
and temperature conditions (n = 3). 
Concentration of 
co-substrate mixture 
ATP specific activity 
/ μM ADP.(mg protein)-1.(min)-1 
ATP-d specific activity 
/ μM ADP.(mg protein)-1.(min)-1 
[1:1 ATP: ATP-d] / μM Mean Sd Mean sd 
0.00 0.00 0.00 0.00 0.00 
200.00 178246.33 44592.66 170742.00 6027.54 
400.00 281766.33 13452.41 293916.33 5886.30 
600.00 355483.33 9654.68 399271.33 12742.09 
800.00 406405.33 13504.47 453103.00 1753.22 
1000.00 408763.66 3532.52 478260.00 2827.49 
1200.00 411279.00 1184.73 485216.66 11602.03 
1400.00 428084.66 654.77 484651.66 5417.05 
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Figure 2.10: Specific activity of acetate kinase against a gradient of 1:1 (ATP: ATP-d). The  
blue series represents specific activity due to ATP-d, and the black series due to ATP. 
 
The data shows that there is a significant increase in AK specific activity in the presence of 
ATP-d, as compared to the activity in the presence of ATP. The concentrations of ATP and 
ATP-d determined from each of the above assays were then used to illustrate the kinetic 
isotope effect on AK. These data are presented in Table 2.3 and Figure 2.11 below. 
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Table 2.3: Kinetic isotope effect on acetate kinase due to ATP (KIEH) and ATP-d (KIED) as a  
function of [1:1 ATP: ATP-d] (n = 3). 
[Sample] ATP ATP-d 
[1:1 ATP: ATP-d] 
/ μM 
Mean (VH/VD) sd Mean (VD/VH) sd 
200.00 1.05 0.03 1.01 0.03 
400.00 0.96 0.03 1.04 0.03 
600.00 0.89 0.03 1.12 0.04 
800.00 0.90 0.03 1.12 0.04 
1000.00 0.86 0.00 1.17 0.01 
1200.00 0.85 0.01 1.17 0.01 
1400.00 0.88 0.01 1.13 0.01 
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Figure 2.11: KIEH and KIED versus [1:1 ATP: ATP-d] for acetate kinase enzyme. The blue  
curve represents KIED and the black curve represents KIEH. 
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2.8.2 Shikimate kinase 
We had previously observed that the enzyme activity of SK changed significantly when 
thawed from storage temperature (-72ºC) to liquid temperature 4ºC, or even during 
subsequent analysis (Kenyon et al. 2011), To determine how the enzyme stability changed, 
by way of its measured activity, when kept at 4
o
C, a simple time course experiment at that 
temperature was performed. Data subsequently generated is furnished in Table 2.4 and 
Figure 2.12 below.  
Table 2.4: SK stability activity as a function of incubation period at 4
o
C (n=3). 
Time / min 
Av. Specific activity / μM 
ADP.(mg protein)
-1
.(min)
-1
 
sd  
0.00 0.00 0.00 
15.00 142.10 0.62 
30.00 98.80 1.19 
60.00 82.89 0.51 
90.00 62.64 0.47 
120.00 39.42 0.65 
180.00 37.91 0.18 
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Figure 2.12: Stability assay for SK at 4ºC against incubation time at constant enzyme and  
ATP concentration. 
Most enzymes at 4ºC was supposed to be inactive since this temperature was not its optimal 
temperature or instead of decreasing as the curve does it was supposed to be increasing but 
since the enzyme was not stable and it would slightly lose its biological activity. Taking this 
into consideration, the following reactions were carried in highly meticulous procedures, 
keeping the time the diluted enzyme remained at 4°C to a consistent minimum. In Table 2.5 
and Figure 2.13 the shikimate assay was inspected for the optimal incubation period, which 
is in the linear phase before the enzyme reached equilibrium. 
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Table 2.5: Shikimate kinase specific activity as a function of ADP concentration against  
incubation time at 37°C. A constant enzyme and ATP concentration was used (n =3) 
Time / min 
Av. Specific activity / μM 
ADP.(mg protein)
-1
.(min)
-1
 
sd / 
μM ADP.(mg protein)-1.(min)-1 
0.00 0.00 0.00 
30.00 201.35 8.98 
60.00 281.80 3.32 
90.00 
357.03 20.47 
120.00 
415.65 7.44 
180.00 
457.47 1.97 
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Figure 2.13: Specific activity SK versus time at constant ATP, temperature and enzyme  
concentration. 
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The incubation period selected for SK was found to be 20 ± 2min as the arrows showing. 
With this data in hand, a return to the kinetic studies was done for AK, but this time on MtSK. 
The data are summarised in Table 2.6 and Figure 2.14 below. 
 
Table 2.6: Specific activity of shikimate kinase as a function of stepwise increases in  
concentration of a 1:1(ATP: ATP-d) mixture under constant incubation time and  
temperature conditions (n = 3). 
Sample name 
ATP specific activity 
/ μM ADP.(mg protein)-1.(min)-1 
ATP-d specific activity 
/ μM ADP.(mg protein)-1.(min)-1 
[1:1 ATP: ATP-d] / μM Mean sd Mean sd 
0.00 0.00 0.00 0.00 0.00 
200.00 610.98 20.25 262.14 1.26 
400.00 819.07 2.45 448.72 17.99 
600.00 1167.57 19.89 511.24 33.64 
800.00 1326.69 74.71 505.84 3.77 
1000.00 1461.14 26.86 496.22 0.14 
1200.00 1412.59 42.25 512.89 2.28 
1400.00 1280.99 11.85 513.82 0.59 
 
 70 
 
Specific activity of SK [1:1 ATP:ATP-d] at constant temperature and time
0 500 1000 1500
0
500
1000
1500
ATP
ATP-d
[1:1 ATP:ATP-d]µM
S
p
e
c
if
ic
 A
c
ti
v
it
y
 (

m
o
le
s
.m
g
 p
r
o
te
in
-
1
.m
in
-
1
)
 
Figure 2.14: Specific activity of shikimate kinase against a gradient of 1:1(ATP: ATP-d).  
The blue series represents specific activity due to ATP-d, and the black series due to  
ATP. 
Unlike what was found for AK, SK showed a significant reduction in specific activity when 
using ATP-d compared to ATP itself. To further substantiate this finding, this data was 
analysed in terms of the kinetic isotope analysis data presented in Table 2.7 and Figure 2.15 
below. 
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Table 2. 7: Kinetic isotope effect on shikimate kinase due to ATP (KIEH) and ATP-d (KIED)  
as a function of [1:1 ATP: ATP-d]. 
[1:1 ATP: ATP-d] / μM KIEH (VH/VD) KIED (VD/VH) 
200.00 2.33 0.43 
400.00 2.35 0.43 
600.00 2.36 0.42 
800.00 2.48 0.40 
1000.00 2.63 0.38 
1200.00 2.82 0.35 
1400.00 2.84 0.35 
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Figure 2.15: KIEH and KIED versus [1:1 ATP: ATP-d] for shikimate kinase. The blue series  
represents specific activity due to ATP-d, and the black series due to ATP. 
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2.8.3 Glutamine synthetase   
From the previous paper of Kenyon et al. (2011), the same incubation period and reaction 
conditions were used when analysing the activity of GS enzyme. This results in saving time 
and reagents by not inspecting the incubation period. With this data (Table 2.8) in hand, a 
return to the kinetic studies was done as before, but this time on GS. The data are summarised 
in Table 2.8 and Figure 2.16 below. 
 
Table 2.8: Specific activity of glutamine synthetase as a function of stepwise increases in  
concentration of a 1:1 (ATP: ATP-d) mixture under constant incubation time and  
temperature conditions (n = 3). 
Sample name 
ATP specific activity 
/ μM ADP.(mg protein)-1.(min)-1 
ATP-d specific activity 
/ μM ADP.(mg protein)-1.(min)-1 
[1:1 ATP: ATP-d] (μM) Mean sd Mean Sd 
235.26 0.00 0.00 0.00 0.00 
915.62 189.90 0.21 3354.80 357.70 
1630.45 1618.50 0.07 7074.20 0.07 
2330.30 3362.00 0.29 10054.30 0.08 
2589.92 4599.90 0.09 12205.90 0.06 
2945.63 5406.60 0.35 12233.90 1.40 
3518.48 7396.40 0.19 12789.70 0.44 
3885.85 7763.80 0.04 12518.10 0.09 
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Figure 2.16: Specific activity of glutamine synthetase against a gradient of 1:1 ATP: ATP-d.  
The blue series represents specific activity due to ATP-d, and the black series due to  
ATP. 
The above data shows a significant increase in GS specific activity in the presence of ATP-d 
when compared to ATP as the concentrations 1:1 ATP: ATP-d were increased. The above 
results are similar to those obtained for AK (Figure 2.10 (p. 64), in that a far higher specific 
activity is obtained for the reaction of GS with ATP-d than for ATP. However this difference 
is higher in GS when compared to the results obtained for AK. This is further explored in the 
kinetic isotope effect analysis presented in Table 2.9 and Figure 2.17 below. 
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Table 2.9: Kinetic isotope effect on glutamine synthetase due to ATP (KIEH) and ATP-d  
(KIED) as a function of [1:1 ATP: ATP-d]. 
[1:1 ATP: ATP-d] / μM KIEH (VH/VD) KIED (VD/VH) 
1277.90 5.07 0.20 
1590.85 4.72 0.21 
1903.80 3.99 0.25 
2216.76 3.27 0.31 
2529.71 2.71 0.37 
2842.67 2.31 0.43 
3155.62 2.02 0.50 
3468.58 1.81 0.55 
3781.53 1.67 0.60 
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Figure 2.17: KIEH and KIED versus [1:1 ATP: ATP-d] for glutamine synthetase. The blue  
series represents specific activity due to ATP-d, and the black series due to ATP. 
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2.9     Comparison of the KIE for AK, SK and GS using ATP and ATP-d 
The time assays for both AK and SK in Table 2.1 or Figure 2.9 (p. 62) and Table 2.5 or 
Figure 2.13 (p. 68) respectively, showed that different enzymes have different optimal 
incubation periods for the reaction conditions specified here. AK incubation period was 
found at 25 ± 3min while the SK incubation period was 20 ± 2min. GS had been optimised in 
terms of incubation period previously (Kenyon et al., 2011); the published incubation period 
was thus employed for GS. 
The SK stability assay in Table 2.4 (p. 66) or Figure 2.12 (p. 67) was used to verify the 
instability of diluted SK when kept at 4
o
C after thawing from the -72ºC storage temperature. 
A steady drop in the specific activity of SK was found when kept at 4
o
C for an increasing 
length of time, as shown by the graph sloping down in Figure 2.12 (p. 67). 
When the specific activities of the enzymes were determined with increasing concentration of 
1:1 ATP: ATP-d, AK in Table 2.2 (p. 63) or Figure 2.10 (p. 64) showed higher specific 
activity with ATP-d than ATP. Similar findings were observed against GS, as seen in Table 
2.8 (p. 72) or Figure 2.16 (p. 73). 
However, when SK was used [Table 2.6 (p. 69) and Figure 2.14 (p. 70)], higher specific 
activity was found with ATP than ATP-d. KIE graphs of AK [Table 2.3 (p. 65) or Figure 
2.11 (p. 65)] and GS [Table 2.9 (p. 74) or Figure 2.17 (p. 74)] have similar shapes, showing 
increasing KIED with decreasing KIEH, implying similar behaviour in these two enzymes. 
However, the opposite trend was observed for SK’s KIE [Table 2.7 (p. 71) or Figure 2.15 (p. 
71)]. By way of reviewing the KIE data generated in this particular study, both primary and 
secondary KIE’s were observed, e.g. if AK and GS in Figure 2.11 (p. 65) and Figure 2.17 (p. 
74) were secondary KIE then the SK in Figure 2.14 (p. 70) was the primary KIE. At this 
point, an attempt was made to clarify the enzyme’s behaviour when comparing the KIE in the 
presence of ATP and ATP-d. In general, the KIE thus described can be used as a convenient 
tool for tracking the mechanistic details of the interactions between the reactants and the 
enzyme binding site following the deuteration process (Hennig, Oswald, & Schmatz, 2006; 
Wade, 1999). Primary KIE occurs when the covalent bond of an isotopic (C-D) atom is 
broken or formed. Secondary KIE occurs when a covalent bond in an isotopic (C-D) atom is 
not directly involved in bond cleavage or formation, but occurs next to the site where 
cleavage occurs, resulting in a secondary bond which is both steric and inductive (Wade, 
1999). 
Comparison of the energy used by both KIE types during bond formation and breaking, 
results in the primary KIE requiring a higher energy than the secondary KIE (Turowski et al., 
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2003; Wade, 1999). In enzymatic reactions of this kind, the secondary KIE is essential, 
because the larger size of the deuterium atom causes a reduction of vibration frequency of C-
D bond compared to C-H bond (Hennig et al., 2006; Turowski et al., 2003). This results in a 
decrease in the binding affinity of a deuterated molecule compared to its protonated 
counterpart for the same enzyme (Turowski et al., 2003); Wade, 1999).  
From the KIE analysis in the present study, particularly which determined for AK and GS, 
could be of the secondary kind while the SK could be primary kind or vice versa based on 
their KIE graphs. This secondary KIE most likely indicated that the deuterated ATP substrate 
caused the KIED to increase until the AK or GS reactions reached their equilibrium states. 
Speculation about the mechanism by which AK or GS uses ATP, probably implicates the C8-
H atom directly in the suspected mechanism of action, being based on the shape of the graphs 
Figure 2.11 (p. 65) and Figure 2.17 (74). On the other hand, the SK data generated in this 
study Figure 2.15 (p. 71) could be a primary KIE. However, follow up on this speculation 
requires additional experimentation beyond the scope of the present study. 
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CHAPTER 3: THE KINETIC ISOTOPE EFFECT (KIE) IN ACETATE KINASE 
AND SHIKIMATE KINASE IN THE PRESENCE OF IMIDAZOLE- OR PURINE-
BASED INHIBITORS IN EITHER THEIR PROTONATED OR DEUTERATED 
FORMS 
INTRODUCTION 
This chapter focuses on changes in activity of shikimate kinase (SK) and acetate kinase (AK) 
caused by protonated and deuterated analogues of their substrates. All assays were designed 
so that enzymes were able to perform at their optimal rates by using standardised reagents 
under optimised temperature and pH conditions. The reaction rates were determined in the 
presence of protonated or deuterated substrates in a 1:1 ratio of enzyme to substrate. 
Comparison of the effects of these substrates on SK or AK activity was done graphically. 
3.1   Enzyme modulation or inhibition 
Enzyme inhibition is defined as the reduction of the rate of enzyme activity or enzyme 
specific activity due to the action of an added compound or substrate in an enzyme-catalysed 
reaction (Martiny-Baron et al., 1993). The term ‘modulator’ is used more generally to label 
the decrease (inhibition) or increase (activation) of specific activity of a given enzyme as a 
result of the presence of modified substrate (Saboury, 2009). This study deals with modulator 
molecules from which inhibitors are to be selected based on the % activities of AK and SK 
assayed with these materials. To simplify things, the % activities for these studies were 
expressed as: 
% specific activity = [specific activity with inhibitor/specific activity without inhibitor] x 100 
Both the reaction with and without inhibitor materials were prepared simultaneously under 
identical conditions. 
There are two kinds of inhibition, namely reversible and irreversible inhibition (Perloff et al., 
2009). In reversible inhibition, the inhibitors can be washed away from the enzyme by a 
process such as dialysis, or by increasing the concentration of substrate; in this particular 
method, the enzyme does not lose its biological activity (Martiny-Baron et al., 1993). By 
contrast, when an irreversible reaction occurs, the inhibitors cannot be removed or washed 
away; when this method is used, the enzyme loses its biological activity. In general, with 
reversible reactions, the weak or non-covalent bonds dominate, whereas with irreversible 
inhibition, covalent bond formation between an enzyme and inhibitor predominate (Saboury, 
2009). 
 78 
 
There are four types of reversible inhibition, namely competitive, non-competitive, 
uncompetitive and mixed inhibition (Saboury, 2009). Competitive inhibition occurs when 
there is a physicochemical resemblance between the substrate and the inhibitor, resulting in 
competition between the two for the binding site of the enzyme. With non-competitive 
inhibition, the substrate and inhibitors are generally dissimilar, binding simultaneously at 
different locations on the enzyme. This generally results in allosteric (conformational) 
modification of the enzyme, translating into a lower reaction rate. This study does not focus 
on the type of inhibitor used, but rather with identifying inhibitors and then subsequently 
trying to determine what the nature of inhibitor interaction is with a particular enzyme. 
Initially, the modulators were tested at 100µM and 1000µM concentration against the various 
enzymes to determine the change in % specific activity. Once substrate preparations causing 
decreased enzyme activity were identified, IC50 inhibition constants were determined for 
these selected materials only. This was done on both AK and SK enzymes. A similar 
procedure was performed on the three products synthesised from 2,6-dichloropurine to the 
point of inhibition of the enzyme’s specific activities; however, IC50 values were not 
determined for these compounds as this was considered beyond the scope of the study. 
3.1.1     IC50 determination. 
In enzymology, dose-response refers to the manner in which the changing concentration of a 
molecule affects the activity of the protein target molecule (Schmidt and Ebel, 1987). 
Generally, the dose-response curve is sigmoidal, with the value at 50% maximum activity 
being characteristic of the enzyme against the particular target molecule. This value is 
referred to as either IC50 (in the case of a specific protein) or EC50 (when a cell, tissue or 
organism is used) (Shoichet, 2006). The dose-response curve consists of a plot of 
log[inhibitor] against enzyme specific activity in response to added inhibitor (Shoichet, 2006) 
The standard IC50 curve yields four parameters, namely maximum response, minimum or 
baseline response, the slope and IC50 value (Bella and Tabesh, 1985; Perloff et al., 2009). The 
magnitude between the baseline and the maximum of the dose curve along the y-axis defines 
the efficacy of the compound, particularly if the deuterated compound has a higher efficacy 
than its protonated counterpart. The potency of a given compound is based on how the curve 
curls along the x-axis, in other words the manner in which the graph shifts along the x-axis. 
The IC50 values for the protonated and deuterated compounds were determined in a 
concurrent fashion. In this way a direct comparison between protonated and deuterated 
analogues was achieved.  
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3.2    Materials and methods 
3.2.1 Activity of AK in the presence of protonated imidazole-containing 
materials and their deuterated analogues 
The AK activity assay involving ten compounds, was prepared as follows: 10ml tubes 
containing a solution mixture of 26.67mM Tris-HCl, pH 7.5, 3.67mM sodium acetate, 34µM 
MgCl2 and 0.25pg/ml AK enzyme was diluted with deionised water to reach a total volume 
of 7.7ml. The solution mixture was incubated at 37
o
C for 5min to allow the solution to reach 
the optimal temperature for the enzyme to function. After 5min, 330µl of a 100μM solution 
of either the protonated or deuterated imidazole-containing compound in deionised water was 
added. Lastly, 1.2μl of a 60mM ATP solution was added to the enzyme / inhibitor mixture, 
and the solution was incubated at 37
o
C for 25min. Each reaction mixture was stopped with 
2µl of 100mM aqueous TCA. All the reactions were loaded into HPLC vials in triplicate 
(110µl) and the concentration ADP determined in each. The specific activity was calculated 
for each inhibitor from these data and a graph constructed with the aid of Graph Pad Prism 
software. 
3.2.2 Activity of AK in the presence of synthetic purines  
Six synthetic purines (1g each) in 1.5ml Eppendorf tubes were dissolved in 1000µl deionised 
water. These materials were assayed as outlined in 3.2.1, except that the assays were run at 
two different concentrations, concurrently, in two 1.5ml Eppendorf tubes, namely at 57μg/l 
and 29μg/l. After quenching, all the reaction solutions were analysed for ADP concentration 
by HPLC, done in triplicate as previously (p. 60). 
3.2.3 SK activity in the presence of 10µM protonated imidazole-containing 
compounds and their deuterated analogues 
A 5ml of a solution made up of 100mM KH2PO4/K2HPO4 pH 6.8, 20µM MgCl2, 10mM KCl, 
2mM shikimic acid and 7.5ng/ml SK enzyme was prepared as the stock reaction solution. 
The solution was then vortexed to ensure thorough mixing. Into 1.5ml Eppendorf tubes were 
placed 0.18µl of 20mM solution of the protonated or deuterated modulator, in nano water 
(10µM modulator in reaction). Thereafter, 330µl of the stock reaction mixture was pipetted 
into each 1.5ml Eppendorf tube containing the modulator compound, which was then mixed 
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and incubated at 37
o
C for 5 min. Following on this, 1.4µl of 60mM ATP was then added to a 
concentration of 0.24mM ATP in the reaction, with nano water used for the blank reaction. 
All the mixtures were vortexed to mix and incubated in a 37
o
C incubator for 20min, then 
quenched with 2µl of 5.7mM EDTA. Each terminated reaction was then centrifuged at 
13000rpm for 2min, followed by triplicate HPLC analysis of 110µl aliquots for ADP 
concentration. Data generated for measuring conversion of ATP to ADP was graphed using 
Graph Pad Prism 6 software. 
3.2.4 Activity of SK in the presence of 10µM and 100µM protonated imidazole-
containing compounds  
The activity assay was performed as in section 3.2.3, except that 1.78µl and 17.8µl of a 
20mM protonated modulator solution were used, to make a concentration of 10µM and 
100µM of protonated imidazole compound in solution. The reactions were terminated and 
analysed as before. 
3.2.5 Activity of SK in the presence of 10µM and 100µM deuterated imidazole-
containing compounds  
The activity assay was performed as in section 3.2.3, except that 1.78µl and 17.8µl of a 
20mM deuterated modulator solution was used to make a concentration of 10µM and 100µM 
of deuterated imidazole compound in solution. The reactions were terminated and analysed as 
before. 
3.2.6 Activity of SK in the presence of 100µM protonated imidazole-containing 
compounds or their deuterated analogues 
The activity assay was performed as for section 3.2.3, except that 1.78µl of a 20mM 
protonated and deuterated imidazole modulator solution was used to make a concentration of 
100µM of protonated and deuterated imidazole compound in solution. The reactions were 
terminated and analysed as before. 
3.2.7 Inhibition of SK by synthetic purines 
Solutions of six synthetic purines were prepared from 1g of material in 1000µl nano water, as 
a standard solution for each sample. A 20µl amount of each standard solution was diluted 
with deionised water to a final concentration of 57μg/l, while a 10µl subsample was diluted to 
29μg/l, both to a final volume of 350µl. The solutions were added to assay mixes as described 
in section 3.2.3 and analysed by HPLC as previously described. 
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3.2.8 Shikimate kinase IC50 assays 
A series of 1:5 (v/v) dilutions of protonated or deuterated imidazole-containing compounds 
(made from 40µl of the stock inhibitor solution, or each successive diluted inhibitor solution 
in 160µl deionised water) was prepared for the each selected inhibitor. The assay was 
performed as in section 3.2.3, with a blank of deionised water instead of inhibitor. The 
stopping reagent was added to the blank mixture before the addition of ATP. The 
‘experimental’ tube was also prepared as for the blank, except that the stopping reagent was 
not added before incubation. Analysis was carried out as in section 3.2.3. 
3.3   Results and individual discussion of AK and SK activity in the presence of 
protonated substrates and their deuterated analogues.  
3.3.1 Acetate kinase  
The following figures and tables show the altered activity of acetate kinase when imidazole-
containing protonated compounds and their deuterated analogues were added to the AK-
catalysed reaction. The change in % activity was compared to the % activity of 
‘experimental’ reaction as reference, since it was prepared in the absence of inhibitor. These 
assays tested for the alteration of % activity when the concentration of each compound was 
standardised at 100 µM, compared to changes in % activity when these compounds were 
subsequently deuterated. The % AK activity was also tested for the synthetic protonated 
purine products at 10µM and 10µM. 
Table 3.3.1: Specific activities of assorted imidazole-containing compounds and their  
deuterated analogues against AK at 100µM. 
Type of Compound 
100µM Protonated imidazole 
compounds 
100µM Deuterated imidazole 
compounds 
Sample name Avg SP% SD Avg SP% SD 
Blank 5.43 6.40 5.43 5.45 
Experiment 100.00 0.00 100.00 0.00 
6-Benzylaminopurine 80.15 2.80 23.73 5.40 
1-Methylimidazole 111.52 3.65 88.12 7.31 
4-Nitroimidazole 137.87 8.49 77.50 8.20 
1-Butylimidazole 111.52 2.22 118.71 7.34 
4-Imidazolecarboxaldehyde 97.28 5.68 105.15 7.97 
1-Methylbenzimadazole 130.65 5.60 101.46 9.02 
Benzimidazole 125.23 7.36 113.92 8.79 
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2,6-Diaminopurine 116.16 4.14 108.11 8.88 
1-Vinylimidazole 122.35 10.52 99.94 6.74 
 
Alteration % activity by 100µM assorted imidazole-containing
 compounds and their deuterated analogues against AK
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Figure 3.3.1: Comparison of the specific activity of AK in the presence of either protonated  
(black) or deuterated (red) imidazole-containing compounds at 100µM. 
In Figure 3.3.1 few compounds are shown to inhibit AK activity, with most promoting it 
instead. The exceptions were with the deuterated forms of 6-benzyl-aminopurine, 
4-nitroimidazole, 1-methylimidazole and, marginally, 1-vinylimidazole and 
2,6-diaminopurine. The protonated form of 6-benzyl-aminopurine may inhibit, but the error 
recorded prevents concrete assessment of this. The deuterated 6-benzylaminopurine was the 
strongest inhibitor of AK activity; however, this compound formed a precipitate when added 
to the reaction. As such, based on these results, it can be speculated that a compound comes 
out of solution once its’ reactive site becomes folded or altered, effectively preventing any 
further chemical reactivity. 
The following Table 3.3.2 and Figure 3.3.2 show the effects of synthetic purines on AK 
activity at 10μM and 100μM. 
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Table 3.3.2: Alkylated purine products that enhance or lower the specific activity of AK. 
 
Concentration 10µM of alkylated purine 100µM of alkylated purine 
Sample Avg SP% SD Avg SP% SD 
Blank 0.00 0.00 0.00 0.00 
Experiment 100.00 0.00 100.00 0.00 
1-Methylpurine 64.43 3.93 152.87 17.48 
1-Ethylpurine 87.63 11.41 103.01 8.15 
2-Ethylpurine 115.45 28.15 198.08 15.07 
1-Benzylpurine 93.29 15.16 134.21 7.11 
2-Methylpurine 
41.01 7.96 18.85 3.20 
2-Benzylpurine 
117.17 6.80 55.94 7.73 
 
Alteration of % activity  when Alkalyted
R-purine compounds were added on the AK
catalysed reaction
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Figure 3.3.2: Specific activity of the alkylated purines against AK at 10µM (black) and  
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100µM (blue). Note the enhanced activity in all cases except 1-methylpurine, 2-
methylpurine, 2-benzylpurine. 
Different alkylated purine compounds were tested for modulation against AK, using methyl, 
ethyl and aromatic benzyl groups attached to purine molecules, and the effect on AK when 
these alkylated groups were added was compared. Only two compounds inhibit AK at the 
higher concentration, namely 2-methylpurine, and 2-benzylpurine. With the other 
compounds, activation of AK was observed at the higher concentration. In 1-methylpurine at 
activation was observed, but 2-methylpurine showed inhibition. The inhibition sequence was 
in the order methyl- > benzyl- > ethyl-. 
3.3.2 Shikimate kinase 
In the following Table 3.3.3 and Figure 3.3.3, the activity of shikimate kinase in the 
presence of imidazole-containing compounds and their deuterated analogues, as well as 
synthetic purines, are explored at 10µM concentrations of protonated or deuterated 
compound. 
 
Table 3.3.3: 10µM SK assays of either protonated imidazole-containing compounds or their  
deuterated analogues resulting in a drop in specific activity. 
Type of Compound 
10µM Protonated imidazole 
compounds 
10µM Deuterated 
imidazole compounds 
Sample Avg SP% SD 
Avg 
SP% 
SD 
Blank 0.00 0.00 0.00 0.00 
Experiment 100.00 0.00 100.00 0.00 
4-Imidazolecarboxaldehyde 85.49 2.66 39.72 2.98 
4(5)-Methylimidazole 116.96 0.89 66.44 4.79 
1-Ethylimidazole 33.14 3.15 62.35 1.44 
1-Methylimidazole 68.80 2.85 30.99 5.15 
4-Imidazolecarboxylic acid 87.98 2.01 66.28 9.42 
1-Methylbenzimidazole 94.47 3.82 58.15 3.04 
5-Chloro-1-methylimidazole 55.49 0.52 4.12 4.69 
2,6-Diaminopurine 54.99 0.84 32.90 2.72 
4-Azabenzimidazole 88.92 2.27 52.82 10.81 
6-Benzylaminopurine 32.97 5.76 20.46 3.37 
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4,5-Dicyanoimidazole 88.63 2.12 55.64 5.46 
Adenine 102.01 2.95 77.08 0.65 
3-(3-Aminopropyl)-imidazole 47.87 1.26 53.51 1.03 
 
Imidazole and their deuterated analogues compounds that lower the % activity of SK
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Figure 3.3.3: Specific activity of SK in the presence of 10µM protonated (black) or  
deuterated (red) imidazole-containing compounds. Note the lower specific activity in  
the presence of the deuterated analogues in all cases. 
The protonated and deuterated imidazole-based compounds were added in the SK in equal 
concentrations to give a direct comparison. In Figure 3.3.3 most of the deuterated imidazole 
compounds showed significant inhibition as compared to their protonated equivalents, except 
for 3-(3-aminopropyl)-imidazole and 1-ethylimidazole. The deuterated and protonated 3-(3-
aminopropyl)-imidazole showed similar inhibition, while protonated 1-ethylimidazole 
showed better inhibition than its deuterated analogue. Some of these protonated imidazoles 
do show inhibition, but this is generally less than when it is deuterated. Majority of the 
deuterated imidazoles in Figure 3.3.3 inhibit SK more than their protonated analogues, 
showing the possible role that deuteration can play in mechanism of reaction. The 
significance of  these data highlights the important effect of deuteration in influencing the  
outcome on enzyme activity, either inhibition or activation, as demonstrated in the examples 
shown in AK and SK specific activity data sets. 
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Table 3.3.4 and Figure 3.3.4 shows selected compounds that activate SK activity, these 
compounds were prepared in reactions that were identical to those in the above table and also 
compared the SK activity of protonated and their deuterated analogues at the lower 
concentration.  
Table 3.3.4: 10µM SK assays of either protonated imidazole-containing compounds or their  
deuterated analogues resulting in an increase in specific activity. 
Type of Compound 
10µM Deuterated imidazole 
compounds  
10µM Protonated 
imidazole compounds 
Sample Avg SP% SD Avg SP% SD 
Blank 0.00 0.00 0.00 0.00 
Experiment 100.00 0.00 100.00 0.00 
1-Vinylimidazole 85.49 2.66 97.03 2.97 
5-Methyl-4-nitroimidazole 114.87 1.77 162.75 2.99 
2-Iodoadenosine 97.21 1.22 113.46 3.45 
4(5)-Hydroxymethyl-imidazole 87.73 3.55 96.97 1.15 
4-Nitroimidazole 100.91 4.64 108.53 3.20 
1-Butylimidazole 105.34 2.20 104.94 0.00 
 
 87 
 
Imidazole and their deuterated analogues compounds that enhance the % activity of
SK
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Figure 3.3.4: Specific activity of SK in the presence of 10µM protonated (black) or  
deuterated analogues (red) imidazole-containing compounds. Note the equal or slightly  
higher specific activity in the presence of the deuterated analogues in all cases. 
As shown in Table 3.3.4 and Figure 3.3.4 the 10µM protonated and deuterated imidazole 
compounds were tested for inhibition of SK activity. All these compounds showed either no 
activity change or an activity enhancement with either the protonated or deuterated imidazole 
compounds. Specifically, deuterated 5-methyl-4-nitroimidazole showed significant activation 
of SK, while the rest of these compounds showed no significant activation. From Figure 
3.3.3(p.85), nine protonated or deuterated compounds that showed moderate inhibition were 
selected and assayed at 100µM and 1000µM protonated compounds in the following Tables 
3.3.5 and Figures 4.3.5. 
Table 3.3.5: Effects of increased inhibitor concentration on SK specific activity in the  
presence of protonated imidazole-containing compounds. 
Type of Compound 
100µM Deuterated imidazole 
compounds  
1000µM Protonated imidazole 
compounds 
Sample Avg SP% SD Avg SP% SD 
Blank 0.00 0.00 0.00 0.00 
Experiment 100.00 0.00 100.00 0.00 
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1-Methylbenzimidazole 88.52 2.81 40.20 0.58 
1-Butylimidazole 60.31 6.68 48.11 1.38 
4-Imidazolecarboxylic acid 97.17 3.11 76.19 1.38 
1-Methylimidazole 41.97 1.30 18.06 0.76 
2,6-Diaminopurine 87.79 7.79 28.54 9.66 
4-Nitroimidazole 96.07 2.17 73.51 0.46 
6-Benzylaminopurine 86.06 1.17 62.67 5.78 
1-Vinylimidazole 74.23 2.99 49.02 4.60 
1-Ethylimidazole 56.87 1.17 15.89 4.52 
 
Alteration of % SK activity by increasing concentration of protonated imidazole compounds
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Figure 3.3.5: Change in SK specific activity in the presence of protonated inhibiting  
imidazole-containing compounds at 100µM (black) and 1000µM (red). A dose- 
response is observed in all instances. 
Figure 3.3.5 shows the inhibition of SK as the concentration of protonated imidazole 
compounds was increased from 100µM to 1000µM, resulting in an increased inhibition as the 
imidazole concentration was increased. All the compounds in Figure 3.3.5 show a significant 
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increase of inhibition and show a dose-response. The deuterated analogues of the nine 
selected compound assayed at lower and higher concentrations are shown in Table 3.3.6 and 
Figure 3.3.6. 
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Table 3.3.6: Effects of increased inhibitor concentration on SK specific activity in the  
presence of deuterated imidazole-containing compounds. 
 
Type of compounds 
100µM deuterated inhibitor 1000µM deuterated inhibitor 
Sample %SP SD %SP SD 
Blank 0.00 0.00 0.00 0.00 
Assay 100.00 1.69 100.00 1.63 
1-Methylbenzimidazole 63.26 2.03 23.69 8.21 
1-Butylimidazole 70.54 3.72 48.89 6.03 
4-Imidazolecarboxylic acid 35.64 5.20 39.88 4.21 
1-Methylimidazole 64.32 2.42 40.85 6.34 
2,6-Diaminopurine 39.77 6.82 37.81 1.91 
4-Nitroimidazole 34.92 2.02 18.57 4.64 
1-ethylimidazole 
 
41.28 1.27 10.11 2.97 
1-Vinylimidazole 30.16 5.87 25.66 4.42 
6-Benzylaminopurine 49.47 2.35 0.00 0.00 
 
Alteration of % SK activity by increasing concentration of deuterated imidazole compounds
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Figure 3.3.6: Change in SK specific activity in the presence of deuterated inhibiting  
imidazole-containing compounds at 100µM (black) and 1000µM (red). A dose-
response is observed in most cases. 
Once again, significant inhibition was observed in Figure 3.3.6 as the concentration of 
deuterated imidazole compounds was increased. The strongest inhibitor at 1,000 µM was 
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6-benzylaminopurine; however, this compound formed a precipitate in the SK reaction. Most 
other compounds show a dose-response except 4-imidazolecarboxylic acid and 
2,6-diaminopurine that showed no significant change. Finally, to determine the effect of 
deuteration, the protonated and deuterated imidazole-containing compounds were compared 
in the SK reaction at 100µM Table 3.3.7 and Figure 3.3.7.  
Table 3.3.7: Comparison of the SK specific activity in the presence of protonated and  
deuterated imidazole-containing compounds at 100μM. 
Type of inhibitor 100µM protonated inhibitor 100µM deuterated inhibitor 
Sample %SP SD %SP SD 
Blank 0.00 0.00 0.00 0.00 
Assay 100.00 1.69 100.00 1.69 
1-Methylbenzimidazole 88.52 2.81 63.26 2.03 
1-Butylimidazole 97.17 3.11 35.64 5.20 
4-Imidazolecarboxylic acid 87.79 7.79 39.77 6.82 
1-Methylimidazole 96.07 2.17 34.92 2.02 
2,6-Diaminopurine 86.06 1.17 41.27 1.27 
4-Nitroimidazole 74.23 2.99 30.16 5.87 
6-Benzylaminopurine 56.87 1.17 9.47 2.35 
1-Vinylimidazole 60.31 6.68 70.54 3.72 
1-Ethylimidazole 41.97 1.30 64.32 2.42 
4(5)-Hydroxymethyl-imidazole 62.94 4.73 89.08 1.22 
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Reduction of  % activity of SK when 100µM  imidazole compounds
and their  deuterated analogues were compared
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Figure 3.3.7: The effect on the SK specific activity in the presence of protonated (black) and  
deuterated (red) imidazole-containing compounds at 100μM. The deuterated analogue 
caused a significant reduction in SK activity relative to their protonated analogues 
except in the last three compounds. 
When selected protonated and deuterated compounds were compared at 100µM, the majority 
inhibited SK. In the majority of imidazole-containing compounds, the deuterated analogue 
showed stronger inhibition except for 1-vinylimidazole, 1-ethylimidazole and 4(5)-
hydroxymethylimidazole. In these cases, the protonated materials had stronger inhibition than 
their deuterated analogues, although the protonated compounds still showed higher inhibition 
than the control.  
The following Table 3.3.8 and Figure 3.3.8 show the results from the substituted purines 
derived from 2,6-dichloropurine against SK. Again the compound concentration was 
increased from 100µM to 1000µM.  
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Table 3.3.8: Comparison of the SK specific activity in the presence of the synthetic purines. 
Type of concentration 100µM concentration 1000µM  concentration 
Sample SP% SD SP% SD 
Blank 0.00 0.00 0.00 0.00 
Experiment 100.00 0.00 100.00 0.00 
1-Methylpurine 105.20 0.41 114.92 0.99 
2-Methylpurine 73.97 0.21 53.36 0.27 
1-Ethylpurine 112.51 0.96 116.48 0.76 
2-Ethylpurine 20.96 0.27 11.78 0.27 
1-Benzylpurine 31.69 1.11 18.43 0.15 
2-Benzylpurine 21.01 0.20 12.57 0.08 
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Figure 3.3.8: Reduction and activation of the activity of shikimate kinase when synthetic  
purines were added at 100µM (black) and 1000µM (blue) compound concentrations. 
From Figure 3.3.8 the assays of the purine products at two concentrations showed that all the 
2-alkylaminopurines significantly inhibited SK and increased inhibition was observed in 
response to increased dose. 1-Methypurine and 1-ethylpurine showed no significant changes 
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or inhibition; however 1-benzylpurine showed significant inhibition. The order of inhibition 
in the 2-alkylaminopurines was methyl < benzyl l≤ ethyl. 
3.3.3 Shikimate kinase IC50 determination 
The following graphs and tables show IC50 results for the three selected compounds from 
Figure 3.3.7(p.91), namely: 1-methylbenzimidazole, 4(5)–hydroxymethylimidazole and 4-
imidazole carboxylic acid. These compounds were selected based on their protonated and 
deuterated inhibition of SK. These compounds were selected on the basis of different % 
inhibition, ie. : less, moderate and higher inhibition. In addition, these compounds were not 
precipitating during reaction with the enzyme. 
The deuterated 4(5)–hydroxymethylimidazole showed 10.92% inhibition, while its 
protonated analogue showed 37.06% when compared to the blank. 1-Methylbenzimidazole 
showed the opposite profile compared to 4(5)-hydroxymethyl-imidazole in that the 
protonated form showed 11.48 % inhibition, while its deuterated analogue lowered activity 
by 36.23%. Both compounds lower the activity around 38% in one form or the other. 4-
Imidazolecarboxylic acid lowered the activity by 12.21% in the protonated form, while its 
deuterated analogue lowered the activity by 60.23%. Based on these observations the three 
compounds were selected from Table 3.3.7(p.90) and Figure 3.3.7(p.91) for IC50 
determination on SK. No IC50 determination was done on AK enzyme due to time 
constraints. 
In this study, the IC50 was calculated for both protonated imidazole and its deuterated 
analogue in each case for comparison. Table 3.3.9(p.94) and Figure 3.3.9 (p.95) show the 
IC50 sigmoidal curves of protonated and deuterated 1-methylbenzimidazole in the SK-
catalysed reaction. A smaller IC50 value indicates a higher inhibition of the activity of the 
enzyme reaction. 
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Table 3.3. 9: Specific activity of shikimate kinase in the presence of a concentration gradient  
of either protonated or deuterated 1-methylbenzimidazole. 
Inhibitor Protonated 4(5)-
hydroxymethylimidazole 
Deuterated 4(5)-
hydroxymethylimidazole 
Log[Inhibitor] Avg SP SD Avg SP SD 
 
4.00 
 
511.95 
 
5.12 
 
247.59 
 
14.12 
 
0.85 
 
511.95 
 
5.12 
 
247.59 
 
14.12 
 
0.78 
 
565.72 
 
3.21 
 
285.25 
 
6.97 
 
0.70 
 
583.98 
 
5.38 
 
329.32 
 
3.72 
 
0.57 
 
617.44 
 
9.68 
 
446.60 
 
12.96 
 
0.40 
 
620.25 
 
12.53 
 
518.85 
 
4.97 
 
0.24 
 
654.97 
 
17.47 
 
549.53 
 
7.23 
 
0.00 
 
717.59 
 
31.85 
 
601.35 
 
7.84 
 
-0.52 
 
746.54 
 
17.32 
 
671.63 
 
0.78 
 
-1.22 
 
707.74 
 
9.46 
 
788.66 
 
9.15 
 
-2.22 
 
731.62 
 
2.25 
 
760.84 
 
5.39 
 
-5.00 
 
798.48 
 
4.70 
 
798.48 
 
4.70 
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Figure 3.3.9: IC50 curve of protonated (black) and deuterated (red) 1-methylbenzimidazole. 
The deuterated 1-methylbenzimidazole has a higher binding affinity for SK as compared to 
the protonated compound. This was confirmed by the IC50 values of 2.59μM (protonated 
material) and 2.04μM (deuterated material), respectively. 
The second compound that was tested for IC50 in SK-catalysed reaction was protonated and 
deuterated 4(5)-hydroxymethylimidazole. The data derived is summarised in Table 3.3.10 
(p.96) and Figure 3.3.10 (p.97). 
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Table 3.3.10: Specific activity data of shikimate kinase in the presence of a concentration  
gradient of either protonated or deuterated 4(5)-hydroxymethylimidazole. 
 Protonated 4(5)-hydroxymethyl-
imidazole 
Deuterated 4(5)-hydroxymethyl-imidazole 
Log[Inhibitor] Avg SP SD Avg SP SD 
4.00 511.95 5.12 247.59 14.12 
0.85 511.95 5.12 247.59 14.12 
0.78 565.72 3.21 285.25 6.97 
0.70 583.98 5.38 329.32 3.72 
0.57 617.44 9.68 446.60 12.96 
0.40 620.25 12.53 518.85 4.97 
0.24 654.97 17.47 549.53 7.23 
0.00 717.59 31.85 601.35 7.84 
-0.52 746.54 17.32 671.63 0.78 
-1.22 707.74 9.46 788.66 9.15 
-2.22 731.62 2.25 760.84 5.39 
-5.00 798.48 4.70 798.48 4.70 
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Figure 3.3.10: IC50 curve of protonated (black) and deuterated (red) 4(5) hydroxylmethyl- 
imidazole. 
In this case, the protonated 4(5)-hydroxymethylimidazole was a stronger inhibitor (IC50 
2.71μM) than its deuterated analogue (IC50 3.62μM). These findings are consistent with the 
behaviour observed in Figure 3.3.7, where deuterated 4(5)-hydroxymethylimidazole 
enhanced SK activity. 
IC50 determination for the SK inhibition assay with 4-imidazolecarboxylic acid is presented 
in Table 3.3.11 (p.98) and Figure 3.3.11 (p.99).  
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Table 3.3.11: SK specific activity data of shikimate kinase in the presence of a concentration  
gradient of either protonated or deuterated 4-imidazolecarboxylic acid. 
Inhibitor 
Protonated 4-imidazolecarbox-
aldehyde 
Deuterated 4-imidazolecarbox-
aldehyde 
Log[Inhibitor] Avg SP SD Avg SP SD 
8.00 1506.74 120.67 567.02 85.04 
0.85 1506.74 120.67 567.02 85.04 
0.78 1688.15 90.18 491.27 30.87 
0.70 2331.25 78.72 782.62 116.39 
0.57 2942.55 34.85 1743.22 21.75 
0.40 3785.50 52.75 2574.25 35.66 
0.24 4226.12 148.51 3140.65 52.34 
0.00 4537.10 68.99 4118.27 6.95 
-0.52 4711.99 17.55 4859.91 18.17 
-1.22 4619.17 513.89 5366.63 26.67 
-2.22 4297.24 59.05 5256.45 63.45 
-10.00 5851.43 4.11 5851.43 4.11 
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Figure 3.3.11: IC50 curve of protonated (black) and deuterated (red) 4-imidazolecarboxylic  
acid. 
In the case of 4-imidazolecarboxylic acid, the deuterated material was a more potent inhibitor 
(IC50 1.77μM) against SK than protonated 4-imidazolecarboxylic acid (IC50 3.05μM). 
3.4   Comparative discussion of AK and SK activity in the presence of 
protonated substrates and their deuterated analogues.  
In general, the deuterated imidazole-containing compounds did not lower the % activity of 
AK. However, the majority of these lower the SK % specific activity. As the concentration of 
protonated imidazole-containing compounds was increased, in the SK-catalysed reaction, the 
specific activity progressively dropped. A nearly identical observation was seen with the 
compound’s deuterated analogues. In certain cases, the deuterated imidazole-containing 
compounds lowered the SK specific activity at least 10% more than their protonated 
analogues, while in others the opposite is true.  
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So when comparing compounds and their alteration of % activity of both AK and SK, it 
could be concluded  that some compounds lowered AK % activity, while others enhanced or 
did not change SK % activity. These changes in enzymatic activity could also have been due 
to a kinetic isotope effecting the transition state during the primary or secondary reaction. 
Another possible cause could be that deuterated compounds slightly change the structure or 
the angle of the covalent C-H/C-D bond because of double mass of deuterium, this could be 
explained by the lock and key analogy.   
When SK specific activity in the presence of synthetic purines was inspected (Figure 3.3.8 (p 
92)) some compounds showed inhibition. Most of the compounds that eluted second showed 
greater inhibition than those which eluted first. For the benzylpurine, both 1
st
 and 2
nd
 products 
resulted in reduced SK specific activity. The majority of synthesised purines enhanced the 
specific activity of AK (Figure 3.3.2 (p 83)), although some were found to inhibit AK, 
namely, 1-methylpurine, 1-ethylpurine, 2-ethylpurine and 1-benzylpurine. 
For IC50 analysis, the three compounds selected based on their inhibition of SK were 4-
imidazolecarboxylic acid, 4(5)-hydroxymethylimidazole and 1-methylbenzimidazole. The 
protonated 1-methylbenz-imidazole’s IC50 value was 2.59μM and the deuterated 
1-methylbenzimidazole’s IC50 value was 2.04μM, meaning that the deuterated analogue was 
a better inhibitor of SK. Similarly, the IC50 values for protonated 4(5)-
hydroxymethylimidazole and deuterated 4(5)-hydroxy-methylimidazole were 2.71μM and 
3.62μM respectively. In this case, the protonated compund was the better inhibitor. The IC50 
values for protonated 4-imidazolecarboxylic acid and the deuterated 4-imidazolecarboxylic 
acid were 3.05μM and 1.77μM respectively, with the deuterated analogue being more potent 
than its protonated companion. 
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CHAPTER 4: DISCUSION, SPECULATION AND CONCLUSION   
4.1    General discussion 
Deuteration has sparked much attention in the field of biochemistry and pharmacology. The 
impact that deuterated compounds has brought to these fields based on the higher potency 
and efficacy can be useful, especially if they inhibit enzymes like shikimate kinase that 
Mycobacterium tuberculosis depends on for survival. In this study, deuteration altered the 
enzyme-catalysed reaction (specific activity) when using three enzyme namely: shikimate 
kinase, glutamate synthetase and acetate kinase. ATP deuteration depends on the incubation 
period and the concentration of the deuterium oxide in the reaction mixture; this was 
confirmed when a different percentage of deuterium oxide was used at a constant 
concentration of ATP and TEA as the catalyst. On ATP deuteration, some of the ATP was 
converted to ADP concurrently. 
Since ATP is a common substrate for shikimate kinase, glutamine synthetase and acetate 
kinase, ATP was deuterated and the kinetic isotopic effect for protonated ATP (KIEH) and 
deuterated ATP (KIED) was determined. For acetate kinase and glutamate synthetase, the 
KIED increased when comparing the specific activity with an increasing concentration of ATP 
or ATP-d, while shikimate kinase showed the opposite trend. The specific activity in the 
presence of deuterated ATP was higher than in the presence of protonated ATP. Nineteen 
commercially obtained imidazole-based were deuterated and assayed against both shikimate 
kinase and acetate kinase. Thirteen compounds inhibited shikimate kinase, while six activated 
it or had no effect. Ten compounds were tested for inhibition of acetate kinase, only three of 
which inhibited, while seven enhanced the acetate kinase activity. 
In all three enzymes, some of the deuterated compounds showed higher inhibition than the 
undeuterated compounds. The effect of deuteration was shown when deuterated ATP was 
compared to protonated ATP. In GS and SK, the deuterated ATP showed the inhibition but 
when tested with AK, activation was observed. The behaviour of these enzymes showed that 
deuteration could be used to regulate the enzyme activity as long as the atom in question is 
mechanistically implicated, as a KIE would show. 
Other compounds that were tested for inhibition were the products derived from 
2,6-dichloropurine, which were synthesized by incorporating three different groups: ethyl, 
methyl and benzyl groups to the 2,6-dichloropurine. Two products were formed for each 
group incorporated. When all purine compounds were tested for acetate kinase inhibition, 
only 2-methylpurine and 2-benzylpurine inhibited in a dose-response fashion; the other 
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compounds activated acetate kinase. When all the purine compounds were tested for 
shikimate kinase activity, the majority of these compounds inhibited except 1-methylpurine 
and 1-ethylpurine which had no effect. 
Lastly three imidazole compounds that inhibited SK were selected for IC50 analysis in order 
to compare their efficacy and potency. These compounds were 4-imidazolecarboxylic acid, 
4(5)-hydroxyimidazole and 1-methylbenzimidazole. These compounds were prepared using 
homologous dilution. The IC50 values of these compounds showed the effect of each 
compound in relation to potency and efficacy. 
4.2 Speculation 
From the KIE analysis it could be speculated that the KIE for AK is a secondary kinetic 
isotopic effect, indicating the C8-H atom is directly involved in the bond formation or 
breaking on the catalysed reaction. However with SK, the opposite effect is observed, 
indicating that the reverse reaction is the dominant mechanistic path by which the KIE is 
operative. The similar effect was also observed when the imidazole compounds were used 
with AK. Similar findings were observed when imidazole and purine compounds and their 
deuterated analogues were used with both SK and AK. Knowledge that a hydrogen atom or a 
weak bond may play a significant role may be probed by replacing it with another atom, such 
as the deuterium atom. 
4.3 Summary 
Deuteration may alter the enzyme activity; however the alteration is not identical when the 
two kinases were compared (AK and SK).  The effect of a deuterated compound in altering 
the activity of SK depends on the type of KIE that is present. When viewing the effect of 
deuterated common substrate in all enzyme (SK, AK and GS), comparing the activity of 
protonated ATP with its deuterated analogy. It was clear that C8-H bond affect the activity 
and relies on whether this bond is directly involved on the formation or breaking of bond 
during the enzyme reaction. When imidazole, purine compound and their deuterated 
analogues were tested for inhibition on these enzymes (SK, AK and GS). This study has 
identified that each compound bind differently with each enzyme which it was applied on, 
this was caused by the shape of the enzyme binding site that each compound possess. While 
the deuterated and its protonated analogy do not bind with the similar fashion when compare 
the activity taken from SK and AK. 
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4.4    Recommendations 
A further analysis of GS is necessary to obtain a more complete selection of chemical 
compounds that may have an inhibitory effect. From this study the KIEH and KIED of SK, GS 
and AK suggested a further analysis to determine the binding and the type of KIE of these 
enzyme. This could be achieved with the Infrared Spectroscopy (IR) studies. Such studies 
might be able to differentiate changes in enzyme activity based on the possibility of a heavy 
hydrogen reduces the molecular vibration, or is it causing different kinds of KIE, ie. affecting   
primary or secondary reactions. 
4.5    Conclusion 
From this study we can draw the following conclusions: 
 Deuteration depends on deuterium concentration, pH and incubation periods. During 
deuteration, hydrolysis occurs at a rate slower than the deuteration reaction. 
 Deuteration begins on the labile or acidic proton in imidazole or purine compounds 
 Replacement of hydrogen with deuterium atom supports the 1st and 2nd reaction rate 
order, while the hydrolysis of ATP to ADP supports the 1
st
 reaction rate order. 
 The KIED increases as the concentration of ATP-d increases using AK and GS, while 
the opposite occurs with SK. 
  Not all the imidazoles and their deuterated analogues inhibit AK or SK; however the 
beginning of chemical library of compounds that do inhibit has been established. 
 Deuteration of imidazole or purine compound increases their inhibition or activation 
character using SK or AK.  
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Appendix part one 
The following structures represent the 
1
HNMR spectra of imidazole- and purine-containing 
compound  protonated and deuterated analogues together with their 3D chemical structure.  
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Figure A.1.2: 2D chemical structure of benzimidazole and its points of deuteration,  
beginning at N9 hydrogen followed by C8, C1, C4, C2 and C3. 
 
 
Figure A.1.3: 
1
H NMR spectrum of benzimidazole is shown in A, B shows deuteration has  
proceeded: the black arrow in A shows the proton at C2, and the red arrow in B shows  
the proton signal is gone. 
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Figure A.1.4: 2D structure of 1-methylbenzimidazole and its points of deuteration, beginning  
at C8, followed by C4, C1, C2 and C3 as the arrows show. 
 
 
Figure A.1. 5: 
1
H NMR spectra of 1-methylbenzimidazole, before and after deuteration. The  
hydrogen atom to be replaced is shown in black in A, and its position in red in B.   
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Figure A.1.6: 2D structure of 6-benzylaminopurine and its points of deuteration, beginning  
at C9 and followed by C8, C3 and then the aromatic hydrogens in the benzene ring. 
 
 
Figure A.1.7: 
1
H NMR spectrum of 6-benzylaminopurine, before and after deuteration. The  
hydrogen atom to be replaced is shown in black in A, and its position in red in B. 
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Figure A.1.8: 2D chemical structure of 2,6-diaminopurine and its points of deuteration,  
beginning at C9 hydrogen and followed by C8. 
 
 
 
Figure A.1.9: 
1
H NMR spectrum of 2,6-diaminopurine before and after deuteration. The  
hydrogen atom to be replaced is shown in black in arrow A, and its position in red  
arrow  B. 
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Figure A.1.10: 2D chemical structure of 2-iodoadenosine and its point of deuteration at C8. 
 
 
 
 
Figure A.1.11: 1H NMR spectrum of 2-iodoadenosine, before and after deuteration. The  
hydrogen atom to be replaced is shown in black in A, and its position in red in B.  
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Figure A.1.12: 2D chemical structure of 4-azabenzimidazole and its points of deuteration,  
beginning at C9 and followed by C8, C1, C2 and C3. 
 
   
Figure A.1.13:  
1
H NMR spectrum of 4-azabenzimidazole, before and after deuteration. The  
hydrogen atom to be replaced is shown in black in A, and its position in red in B. 
 118 
 
 
Figure A.1.14: 2D chemical structure of adenine and its points of deuteration, beginning at  
N9 and N3, followed by C8 and C2. 
 
 
Figure A.1.15: 1H NMR spectrum of adenine before and after deuteration. The hydrogen atom  
to be replaced is shown in black in A, and its position in red in B. 
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Figure A.1.16: 2D chemical structure of 1-ethylimidazole and its points of deuteration,  
beginning at C2 followed by C5 and C4.  
 
 
 
Figure A.1.17: 
1
H NMR spectrum of 1-ethylimidazole, before and after deuteration. The  
hydrogen atom to be replaced is shown in black in A, and its position in red in B. 
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Figure A.1.18: 2D chemical structure of 1(3)-methy imidazole and its points of deuteration,  
beginning at C2 and followed by C4 and C5. 
 
 
Figure A.1.19: 
1
H NMR spectrum of 1(3)-methylimidazole, before and after deuteration. The  
hydrogen atom to be replaced is shown in black in A, and its position in red in B. 
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Figure A.1.20: 2D chemical structure of 4(5)-(hydroxymethyl imidazole and its points of  
deuteration, beginning at N3 and followed by C2 and lastly the C4 position. 
 
 
 
Figure A.1.21: 
1
H NMR spectrum of 4(5)-(hydroxymethyl) imidazole before and after  
deuteration. The hydrogen atom to be replaced is shown in black in A, and its  
position in red in B. 
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Figure A.1.22: 2D chemical structure of 24(5)-methylimidazole and its points of deuteration,  
beginning at N3 hydrogen followed by C2 and lastly the C4 position.  
 
 
Figure A.1.23:  
1
H NMR spectrum of 4(5)-methyl imidazole, before and after deuteration.  
The hydrogen atom to be replaced is shown in black in A, and its position in red in B. 
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Figure A.1.24: 2D chemical structure of 4-imidazolecarborxylic acid and its points of  
deuteration, beginning at N3 and followed by C2 and C5.  
 
Figure A.1.25: 
1
H NMR spectrum of 4-imidazolecarborxylic acid, before and after  
deuteration. The hydrogen atom to be replaced is shown in black in A, and its  
position in red in B. 
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Figure A.1.26: 2D chemical structure of 4-imidazolecarboxyaldehyde and its points of  
deuteration, beginning at N3 and followed by C2 and C5. 
 
 
 
Figure A.1.27: 
1
H NMR spectrum of 4-imidazolecarboxyaldehyde, before and after  
deuteration. The hydrogen atom to be replaced is shown in black in A, and its  
position in red in B. 
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Figure A.1.28: 2D chemical structure of 1-butylimidazole and its points of deuteration,  
beginning at C2 and followed by C4 and C5. 
 
 
 
Figure A.1.29: 
1
H NMR spectrum of 1-butylimidazole, before and after deuteration. The  
hydrogen atom to be replaced is shown in black in A, and its position in red in B. 
 126 
 
 
Figure A.1.30: 2D chemical structure of 1-(3-aminopropyl) imidazole and its points of  
deuteration, beginning at C2 and followed by C4 and C5. 
 
 
 
Figure A.1.31: 
1
H NMR spectrum of 1-(3-aminopropyl) imidazole, before and after  
 deuteration. The hydrogen atom to be replaced is shown in black in A, and its position 
in red in B. 
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Figure A.1.32: 2D chemical structure of 1-vinylimidazole and its points of deuteration,  
beginning at C2 hydrogen and followed by C4 and C5. 
 
 
Figure A.1.33: 
1
H NMR spectrum of 1-vinylimidazole, before and after deuteration. The  
hydrogen atom to be replaced is shown in black in A, and its position in red in B. 
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Figure A.1.34: 2D chemical structure of 4-nitroimidazole and its points of deuteration,  
beginning at N3 and followed by C4 and C2. 
 
 
 
Figure A.1.35: 
1
H NMR spectrum of 4-nitroimidazole, before and after deuteration. The  
hydrogen atom to be replaced is shown in black in A, and its position in red in B. 
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Figure A.1.36: 2D chemical structure of 4,5-dicynoimidazole and its points of deuteration,  
beginning at N3 and followed by C4 and C2.  
 
 
Figure A.1. 37: 
1
H NMR spectrum of 4,5-dicynoimidazole, before and after deuteration. The  
hydrogen atom to be replaced is shown in black in A, and its position in red in B. 
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Figure A.1.38: 2D chemical structure of 5-chloro-1-methylimidazole and its points of  
deuteration, beginning at C2 and followed by C4. 
  
 
 
Figure A.1.39: 
1
H NMR spectrum of 5-chloro-1-methylimidazole before and after  
deuteration the hydrogen atom to be replaced is shown in black in A, and its position  
in red in B. 
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Figure A.1.40: 2D chemical structure of 5-methyl-4-nitroimidazole and its points of  
deuteration, beginning at N3 and followed by C2.  
 
 
Figure A.1.41: 
1
H NMR spectrum of 5-methyl-4-nitroimidazole, before and after deuteration  
the hydrogen atom to be replaced is shown in black in A, and its position in red in B. 
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Appendix part two 
The following figures represent the effect of deuteration when the deuterium oxide 
concentration is increasing together with the incubation period. The most deshielded 
(lefthandmost) protons disappears as the incubation period lengthens .The integrated value 
for the proton signals are also seen to decrease as the hydrogen is replaced. The increasing 
percentage of deuterium oxide is in the order 25, 50, 75 and 100%, while the incubation 
periods are 0, 24, 48, 72, 96, 120 and 144h. 
The 25 % 
1
HNMR spectra 
 
Figure B.1.1: Showing the hydrogen/deuterium replacement at 25% deuterium solution  
before incubation. 
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Figure B.1.2: Showing the hydrogen/deuterium replacement at 25% deuterium solution when  
incubated at 60ºC for 24h. 
 
Figure B.1.3: Showing the hydrogen/deuterium replacement at 25% deuterium solution when  
incubated at 60ºC for 48h. 
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Figure B.1.4: Showing the hydrogen/deuterium replacement at 50% deuterium solution when  
incubated at 60 ºC for 72h. 
 
Figure B.1.5: Showing the hydrogen/deuterium replacement at 25% deuterium solution when  
incubated at 60 ºC for 96h. 
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Figure B.1.6: Showing the hydrogen/deuterium replacement at 25% deuterium solution when  
incubated at 60 0C for 120h. 
 
Figure B.1.7: Showing the hydrogen/deuterium replacement at 25% deuterium solution when  
incubated at 60 
0
C heating block for 144h. 
 136 
 
 
Figure B.1. 8: Showing the hydrogen/deuterium replacement at 50% deuterium solution  
when incubated at 60 ºC for 0h. 
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The 50 % 
1
HNMR spectra 
 
Figure B.1.9: Showing the hydrogen/deuterium replacement at 50% deuterium solution when  
incubated at 60 ºC for 24h. 
 
Figure B.1.10: Showing the hydrogen/deuterium replacement at 50% deuterium solution  
when incubated at 60 ºC for 48h. 
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Figure B.1.11: Showing the hydrogen/deuterium replacement at 50% deuterium solution  
when incubated at 60 ºC for 72h. 
 
Figure B.1.12: Showing the hydrogen/deuterium replacement at 50% deuterium solution  
when incubated at 60 ºC for 96h. 
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Figure B.1.13: Showing the hydrogen/deuterium replacement at 50% deuterium solution  
when incubated at 60 ºC for 120h. 
 
Figure B.1.14: Showing the hydrogen/deuterium replacement at 50% deuterium solution  
when incubated at 60 ºC for 144h. 
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The 75 % 
1
HNMR spectra 
              
Figure B.1.15: Showing the hydrogen/deuterium replacement at 75% deuterium solution  
when incubated at 60 ºC for 0h. 
 
Figure B.1.16: Showing the hydrogen/deuterium replacement at 75% deuterium solution  
when incubated at 60 ºC for 24h. 
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Figure B.1.17: Showing the hydrogen/deuterium replacement at 75% deuterium solution  
when incubated at 60 ºC for 48h. 
 
Figure B.1.18: Showing the hydrogen/deuterium replacement at 75% deuterium solution  
when incubated at 60 ºC for 72h. 
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Figure B.1.19: Showing the hydrogen/deuterium replacement at 75% deuterium solution  
when incubated at 60 ºC for 96h. 
 
Figure B.1.20: Showing the hydrogen/deuterium replacement at 75% deuterium solution  
when incubated at 60 ºC for 120 h. 
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Figure B.1.21: Showing the hydrogen/deuterium replacement at 75% deuterium solution  
when incubated at 60 ºC heating block for 144h. 
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The 100 % 
1
HNMR spectra 
 
Figure B.1.22: Showing the hydrogen replacement at 100% deuterium solution when  
incubated at 60 ºC for 0h. 
 
Figure B.1.23: Showing the hydrogen replacement at 100% deuterium solution when  
incubated at 60 ºC for 24h. 
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Figure B.1.24: Showing the hydrogen replacement at 100% deuterium solution when  
incubated at 60 ºC for 48h. 
 
Figure B.1.25: Showing the hydrogen replacement at 100% deuterium solution when  
incubated at 60 ºC for 72h. 
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Figure B.1.26: Showing the hydrogen replacement at 100% deuterium solution when  
incubated at 60 ºC for 96h. 
 
Figure B.1.27: Showing the hydrogen replacement at 100% deuterium solution when  
incubated at 60 ºC for 120h. 
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Figure B.1.28: Showing the hydrogen replacement at 100% deuterium solution when  
incubated at 60 ºC for 144h. 
